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ABSTRACT 
 
Aflatoxins are fungal metabolites which are toxic, carcinogenic, and mutagenic, and have been 
proposed as altering  immunocompetence and growth in humans. Aflatoxins, together with 
hepatitis B and C, have been recognized as the major risk factors for the development of 
hepatocellular carcinoma (HCC) in parts of Africa and Southeast China. Children are a highly 
susceptible population to environmental carcinogens and a number of studies indicate that 
susceptibility to aflatoxin is greatest in the young. Aflatoxin exposure has been associated with 
growth faltering and immune suppression in young children. Early life exposures could be a 
contributing factor towards the early onset of HCC. 
The undertaken research aimed 1) to assess using specific biomarkers the exposure patterns and 
levels of aflatoxin exposure among nursing Egyptian mothers and their children, 2) to compare the 
exposure levels of the Egyptian children with children from Guinea, a country with a known high 
aflatoxin exposure, and 3) to assess the effectiveness of probiotic supplementation in the reduction 
of the biologically effective dose of aflatoxin exposure in a highly exposed region of Southern 
China. 
In Egypt, 388 lactating mothers were screened for aflatoxins in their breast milk, and 50 of them 
with high aflatoxin M1 (AFM1) levels were recruited for a year of follow up with monthly 
collections of breast milk samples. The aflatoxin exposure of the 50 Egyptian children was 
additionally compared to the exposure of 50 Guinean children by monitoring urinary biomarkers 
of aflatoxin exposure. In China, 90 young adults were selected out of a group of 300, to participate 
in a randomized double blind placebo controlled intervention trial testing the effectiveness of a 
probiotic supplementation in reducing aflatoxin exposure. 
Aflatoxin was found in the breast milk supplied by 138 out of 388 nursing Egyptian mothers 
[median 13.5 pg/ml, IQR (10.27-21.43)]. Non-working status [OR= 2.87, 95% CI (1.2-6.8)], 
obesity [OR= 3.01, 95% CI (1.43-6.33)], high corn oil consumption [OR= 2.21, 95% CI (1.3-
3.7)], number of children (>1) [OR= 1.99, 95% CI (1.09-3.64)], and early lactation stage (<1 
month) [OR=3.57, 95% CI (1.15-1.09)], contributed to the occurrence of AFM1 in breast milk. In 
the follow up cohort, the most dominant factor affecting the presence of AFM1 in breast milk was 
the seasonal effect. AFM1 was observed most frequently during summer months (May-September) 
with the highest rates observed in June [OR 63, 95% CI (7.6, 522)]. The duration of lactation 
[OR= 1.08, 95% CI (1.02, 1.13)] also affected AFM1 presence, while peanut consumption [OR= 
1.69, 95% CI (0.9, 2.9)] hinted at an effect. Exposure of the Guinean children to aflatoxin was 
more prevalent and at higher levels as compared to the Egyptian children (86% vs. 38%, p= 
0.000). Probiotic supplementation in young Chinese adults clearly reduced the biologically 
effective dose of AFB1 as indicated by the urinary excretion of AFB1-N7-guanine adduct 
(probiotic group 0.24 ng/ml, placebo group 0.49 ng/ml, p= 0.005). 
These data would suggest that aflatoxin exposure does occur in children and young adults residing 
in highly exposed regions and measures should be initiated to reduce this exposure. The 
identification and understanding of factors determining the presence of toxicants in human milk is 
important and may provide a knowledge driven basis for controlling the transfer of chemicals to 
infants. Probiotic supplementation could represent affordable and feasible means to reduce the 
bioavailability of aflatoxin and consequently the health risks associated with aflatoxin exposure in 
aflatoxin endemic areas. 
 
National Library of Medicine Classification: QU 120, QW 630.5.M9, WS 125  
Medical Subject Headings: Aflatoxins/adverse effects; Aflatoxins/urine; Biological 
Markers/analysis; Breast Feeding; Child; Infant; China/epidemiology; Egypt/epidemiology; 
Guinea/epidemiology; Maternal Exposure; Milk, Human/chemistry; Milk, Human/toxicity; 
Mothers; Mycotoxins/adverse effects; Probiotics 
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1. INTRODUCTION 
 
Aflatoxins are a family of highly toxic and carcinogenic fungal metabolites produced by 
several species of Aspergillus which frequently contaminate dietary staples (groundnuts, 
maize) all over the world, though mostly in the developing countries mainly due to the 
environmental conditions. Aflatoxins, together with hepatitis B (HBV) and C viruses 
(HCV), have been recognized as the major risk factors for the development of 
hepatocellular carcinoma (HCC) in the high risk incidence regions for the disease. Often 
the regions of high HBV infection rates are the same as those with the highest aflatoxin 
exposure. Individual exposure as assessed by measurements of aflatoxin specific 
biomarkers such as urinary metabolites or albumin adducts, have been repeatedly 
reported in West Africa and Southeast China. In comparison, individual aflatoxin 
exposure in Egypt is known to occur at moderate levels. However, for genotoxic 
carcinogenic substances such as aflatoxins, it is impossible to define a threshold value 
below which there is no risk for human health. 
Children are exceptionally vulnerable and highly susceptible to environmental hazards 
and there is a strong link between growth and health of the fetus and infant and disease 
risk in later life. Aflatoxins are potent carcinogens and in addition, childhood aflatoxin 
exposure has been associated with growth faltering and reduced salivary IgA levels. In 
West Africa, elevated biomarker levels in children have been repeatedly reported, with 
children exhibiting higher biomarker levels when infected with HBV. Maternal 
aflatoxin exposure during the pregnancy and the lactation period leads to in utero and 
early infancy exposures through breast milk contamination. Early pre- and postnatal 
exposure to aflatoxins via mother’s milk or weaning foods could be one of the factors 
contributing to growth faltering and/or the early onset of liver cancer in adulthood. 
Prevention of HCC among high risk populations can be mainly achieved by 
immunization against HBV infection and by reductions of aflatoxin exposure. 
Reductions in aflatoxin exposure can be achieved by several approaches. Where the 
source of contamination is clearly defined, such as in Guinea, West Africa, post harvest 
changes to the way that risk foods are dried and stored have proven to be effective. 
Where dietary sources are less well defined such as in Egypt, reduction in uptake of 
aflatoxins may be achieved by dietary modulation, eg. with chlorophyllin, or probiotics. 
 12 
In the present work, we aimed to investigate the patterns and levels of maternal and 
child aflatoxin exposure in a group of mothers-children in Egypt, and to compare the 
exposure levels of the Egyptian children with children from Guinea, a country with a 
known high aflatoxin exposure. Another goal was to assess the effectiveness of 
probiotic supplementation in the reduction of the biologically effective dose of aflatoxin 
exposure in a highly exposed region of Southern China. The ultimate goal of the present 
work was to create the basis for an intervention to be targeted at reducing maternal and 
child aflatoxin exposure in Egypt. 
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2. REVIEW OF THE LITERATURE 
 
2.1. Aflatoxins and natural occurrence 
 
Primary aflatoxins 
Aflatoxins are the most widely studied group of mycotoxins. They are a family of 
highly toxic and carcinogenic fungal metabolites produced by Aspergillus moulds and 
particularly by the species of Aspergillus flavus, Aspergillus paraciticus and the rare 
Aspergillus nomius. A. flavus produces aflatoxins B1 (AFB1) and B2 (AFB2), whereas A. 
parasiticus produces also aflatoxins G1 (AFG1) and G2 (AFG2) (IARC 1993). Figure 1 
shows the chemical structures of the four major naturally occurring aflatoxins produced 
by the Aspergillus species. 
 
 
 
 
 
 
 
            Aflatoxin B1                                                         Aflatoxin B2                                                   Coumarin 
 
 
 
 
 
 
 
           Aflatoxin G1                                                          Aflatoxin G2                                                      Furan 
 
Figure 1: The chemical structures of the major naturally occurring aflatoxins. 
 
Aflatoxins were first identified in 1961 in animal feed contaminated by Aspergillus 
fungi (Sargeant et al. 1961). The name ‘aflatoxin’ was introduced by Nesbitt et al. 
(1962) from the abbreviation of ‘A. flavus toxin’. Aflatoxins are strongly fluorescent 
under ultraviolet (UV) light and the four major aflatoxins are named accordingly to the 
color of the emitted light; B for blue and G for green. The subscripts refer to the 
chromatographic mobility of the toxins during thin-layer chromatography (Sargeant et 
al. 1963, Bennett and Klich 2003). 
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Chemically, aflatoxins are difuranocoumarins composed from two furans and a 
coumarin ring (Figure 1). The unsaturated bond in the terminal furan ring carbons 8 and 
9 (atoms are numbered according to instructions given by the International Union of 
Pure and Applied Chemists, IUPAC) is the site at which its bio-activation forms a 
highly reactive epoxide structure. AFB1 is the most potent of the aflatoxins and 
consequently the most widely studied. 
 
Aflatoxins in milk 
Shortly after the discovery of aflatoxins, food safety concerns about the presence of 
aflatoxin residues in milk (Allcroft and Carnaghan 1963) prompted numerous studies on 
the conversion of AFB1 in dairy cattle feed to aflatoxin metabolites in milk. This lead to 
the identification of aflatoxin M (De Longh et al. 1964), a name derived to indicate its 
original isolation from milk. The structure of aflatoxin M was revealed by Holzapfel 
and coworkers (1966), who found that aflatoxin M consisted of two components 
designated as aflatoxin M1 (AFM1) and M2 (AFM2), and which were identified as the 4-
hydroxyderivatives of AFB1 and AFB2, respectively. Later, another hydroxyderivative 
of AFB1 was detected in milk (Lafont et al. 1986) AFM4, but the knowledge about 
AFM4 is very limited. Considerable attention has been paid to AFM1. A Detailed 
discussion of AFM1 can be found in chapter 2.2, under the sections of biotransformation 
and excretion of aflatoxins. 
 
Natural occurrence of primary aflatoxins 
Aspergillus fungi are common contaminants in the agricultural envrionment. Fungal 
growth and subsequently dietary aflatoxin contamination are ubiquitous in areas of the 
world with hot and humid weather conditions as in several African (El-Nezami et al. 
2000b, Wild and Hall 2000, Wild and Turner 2002) and Asian countries (Groopman et 
al. 1992a, Qian et al. 1994). In Africa, A. flavus and A. paraciticus are widely 
distributed whereas in south-east Asia, A. flavus is present to the virtual exclusion of all 
other species (IARC 1993). The fungal infection of the crops can occur pre-harvest in 
the field or post-harvest during transportation or storage. Pre-harvest infections are 
mostly associated with drought stress, whereas post-harvest contamination occurs 
mostly during the storage of the crops under conditions that favor mould growth 
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(Bennett and Klich 2003). During storage, usually the most important variables are the 
moisture content of the substrate and the relative humidity of the surroundings (Wilson 
and Payne 1994). 
Human dietary exposure to aflatoxins at levels of nanograms to micrograms per day 
occurs mainly through consumption of a wide variety of contaminated crops like maize, 
groundnuts, cottonseed, soybeans, sorghum, rice and wheat (IARC 1993). The high 
level contamination of groundnuts and maize are of particular concern since these crops 
comprise the dietary staples of many populations in the developing countries (Table 1). 
In aflatoxin contaminated samples, AFB1 is the compound most frequently present 
followed by AFG1. AFB2 and AFG2 are typically present at much lower quantities 
(IARC 1993). 
The aflatoxin limits for human foods vary from 4 to 30 µg aflatoxin /kg of food, with 
the limit depending on the country (Williams et al. 2004). The maximum limits set by 
the European Commission for cereals, nuts, dried fruits and processed products intended 
for human consumption are 2 µg/kg for AFB1 and 4 µg/kg for total aflatoxins 
(AFB1+AFB2+AFG1+AFG2) (EC 2001). For the health protection of the infants and 
young children, a vulnerable population group, the European Commission states that it 
is appropriate to establish the lowest maximum level that is achievable through a strict 
selection of the raw materials used for the manufacturing of the infant milk formulas 
and baby foods. The maximum permissible limits of AFB1 in baby foods and processed 
cereal based foods intended for infants and young children is set at 0.1 µg/kg, and for 
AFM1 in infant foods, milk formulas and follow up formulas at 0.025 µg/kg (EC 2004). 
The European Commission has fixed 0.05 µg/kg (EC 2001) as the limit for AFM1 in 
milk and 0.05 mg/kg (EC 1999) as the limit for AFB1 in feeds. The action level for 
AFM1 in milk and dairy products in the United States is tenfold higher (0.50 µg/kg) than 
the current level in the EC. In Egypt, there is a little known about levels of AFM1 in the 
milk of lactating animals. The presence of aflatoxins in feed however has been reported 
(Abdelhamid 1990), with mean AFB1 levels claimed to be 58± 29 µg/kg (range 4-577), 
i.e. above the limits set by the European Commission. 
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Table 1: Occurrence of primary aflatoxins in staple foods in developing countries 
Country Foods Aflatoxins % of detection 
(n) 
Mean level or 
range, µg/kg 
Reference 
Egypt corn AFB1, AFB2 23 (40) NS* (El-Shanawany 
et al. 2005) 
Egypt corn and corn 
products 
AFB1 
AFG1 
2.5 (57) >35000 
>16000 
(El-Sayed et al. 
2003) 
Egypt peanut and seeds 
spices 
herbs and plants 
dried vegetables 
cereal grains 
AFB1 82 
40 
29 
20 
36 
24 
25 
49 
20 
36 
(Selim et al. 
1996) 
Egypt spices AFB1, AFB2 
 AFG1, AFG2 
13 (120) 8-35 (El-Kady et al. 
1995) 
Egypt corn, rice, wheat, 
cotton seed, 
peanuts 
AFB1, AFB2 
 AFG1, AFG2 
44 (95) 5-400  (Abdelhamid 
1990) 
Egypt corn, lentils, 
beans, peanuts, 
cottonseed 
AFB1, AFB2 
 AFG1, AFG2 
33 (42) 3-12 (Girgis et al. 
1977) 
China corn 
groundnuts 
AFB1 70 
24 
36.5 (max 1098) 
80.2 (max 437) 
(Wang and Liu 
2006) 
China corn 
peanut oil 
rice 
AFB1 76 (30) 
66 (30) 
23 (30) 
0.4-128 
0.1-52 
0.3-2 
(Wang et al. 
2001) 
China maize AFB1, AFB2, 
AFG1 
85 9-2496 (Li et al. 2001) 
Guinea groundnuts 
corn 
rice 
AFB1 61 (46) 
22 (9) 
0 (66) 
1-112 
NS* 
NS* 
(Turner et al. 
2002) 
Gambia peanuts AFB1, AFB2, 
AFG1,AFG2 
87 (47) 1-100 (Wild et al. 
1992) 
Kenya corn AFB1 54 (480) 0-58000 (Muture and 
Ogana 2005) 
Benin and 
Togo 
corn, groundnuts AFB1 11.6 (502) 
4.6 (175) 
0-≥20 (Egal et al. 
2005) 
Benin corn AFB1 100 (3)** 15.2 (Fandohan et al. 
2005) 
* not specified, **three replicates of 5 kg each 
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2.2. Toxicokinetics of aflatoxins 
 
Four processes are involved in toxicokinetics: absorption, distribution, 
biotransformation, and elimination (Hsieh and Wong 1994). These are inter-related 
processes as illustrated in the following figure (Figure 2). AFB1 is both the most 
frequently occurring and the most potent of the naturally occurring aflatoxins and thus 
will be the focus of this section. Other aflatoxins will be discussed only when relevant. 
Excretion of AFB1 metabolites from the human body will be discussed here, but further 
information on aflatoxin metabolites in human biological fluids will be presented in 
chapter 2.3.2 Biomarkers of aflatoxin exposure. 
 
 
Figure 2: Toxicokinetics of aflatoxins 
 
2.2.1. Absorption 
Absorption is the process by which toxicants gain entrance into the body but the extant 
of absorption varies greatly depending on the route of exposure. The absorbed dose 
(internal dose) is only a fraction of the exposure via skin, oral or respiratory tract routes 
(external dose). For substances injected directly into the body, the external dose is the 
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same as the internal dose. The oral intake is the main route of exposure to aflatoxins. 
AFB1 is a relatively low molecular weight, lipophilic molecule, indicating that there is 
likely to be efficient absorption after ingestion. Animal studies have shown that under 
normal conditions 50% of the orally administered dose of AFB1 is quickly absorbed 
from the duodenal region of the small intestine (Coulombe and Sharma 1985, Kumagai 
1989) and then reaches the liver via the hepatic portal blood supply (Wilson et al. 
1985). Aflatoxins have to pass through the gastrointestinal mucosa, crossing several 
membranes before entering the systemic circulation. They are absorbed by passive 
diffusion and the lipophilicity of the aflatoxin determines the rate of absorption. For 
AFB1 the rate of absorption is considerably higher than for AFG1, which is a less 
lipophilic analogue (Kumagai 1989). 
 
Enterohepatic circulation 
Absorption of aflatoxins from the gastrointestinal tract can also occur via of the 
enterohepatic circulation (Hsieh and Wong 1994). This is a process of excretion of 
aflatoxin metabolites from the liver via the bile into the intestinal tract and reabsorption 
and return to the liver by the portal circulation. Since aflatoxin metabolites are excreted 
in the bile as water soluble glucuronides, they are not likely to be reabsorbed as such. 
However, enzymes present in the intestinal microbiota are capable of hydrolyzing some 
glucuronide conjugates, and thereby release the less polar compounds that may then be 
reabsorbed. 
 
2.2.2. Distribution 
Distribution is the process during which an absorbed chemical is transferred from its 
site of absorption to other areas of the body. Following absorption, AFB1 is 
concentrated in the liver not only after oral exposures but also after intravenous and 
intraperitoneal dosing. This is due to the high permeability of the hepatocyte membrane 
for AFB1, and its active metabolism and subsequent covalent binding with hepatic 
macromolecules (Busby and Wogan 1984). The kidneys also concentrate AFB1 but to a 
much lesser extent (Hayes et al. 1977, Hsieh and Wong 1994). The major route for 
distribution of an absorbed xenobiotic, e.g. aflatoxins, is via the blood circulation and 
this is greatly affected by binding of the compound to plasma proteins (Hsieh and Wong 
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1994). Within the circulating blood, the non-bound (free) portion is in equilibrium with 
the bound portion. However, only the free substance is available to pass through the 
capillary membranes. Given the high efficiency of the liver to extract free AFB1 from 
the blood, binding of AFB1 to serum albumin already at the site of intestinal absorption  
can be considered as a major detoxification mechanism, preventing aflatoxin from 
evoking potential cell interactions (Hsieh and Wong 1994). 
 
2.2.3. Biotransformation 
Biotransformation or metabolism is the process by which the body transforms the 
substances into new chemicals (metabolites) i.e. a process by which the parent 
compound is eliminated from the exposed biological system. The aflatoxins, like other 
xenobiotics undergo phase I (activation) and phase II (detoxification) biotransformation. 
Although the primary site of aflatoxin metabolism is the liver (and to a lesser extent in 
the kidney), the gastrointestinal tract also participates in this function (Eaton et al. 
1994). 
 
Phase I metabolism (AFB1 activation, macromolecule binding and formation of 
hydroxylated metabolites) 
The cytochrome P450 (CYP450) mixed-function monooxygenase system is the most 
important element in Phase I reactions of xenobiotics modifying them by adding a 
functional group. CYP450 enzymes are a family of haemoproteins that catalyze the 
metabolism of a large number of xenobiotics, including aflatoxins (Guengerich 1999). 
Although predominantly localized in the endoplasmic reticulum of liver cells, 
CYP450’s are additionally present in the lung, bladder, uterus, kidney, and small 
intestine (Krishna and Klotz 1994). Of the CYP450 enzymes, CYP1A2 and CYP3A4 
are the main enzymes responsible for the metabolism of the absorbed aflatoxins 
(Essigmann et al. 1982, Forrester et al. 1990, Omiecinski et al. 1999). CYP3A4 is one 
of the major CYP enzymes in the liver (Guengerich et al. 1998) and it is the dominant 
P450 involved in the activation of AFB1 at all AFB1 concentrations. 
Oxidative activation of the 8,9 double bond in the terminal furan moiety of AFB1 by 
CYP450 1A2 and 3A4, forms the 8,9-AFB1 epoxide (Johnson and Guengerich 1997). 
The epoxide has two stereomeric forms, exo and endo-epoxide (Figure 3). 
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                  Aflatoxin B1-8,9-exo-epoxide  Aflatoxin B1-8,9-endo-epoxide 
 
Figure 3: The exo and endo-epoxides of aflatoxin B1-8,9-epoxide. 
 
AFB1 epoxides are highly unstable in water (t1/2 of <1 sec, 23o C and neutral pH) and 
rapidly and non-enzymatically hydrolyse to the more stable AFB1-8,9 dihydrodiol 
(Guengerich et al. 1998) AFB1-8,9 dihydrodiol, can undergo ring opening and this 
results in the formation of a resonating dialdehyde phenolate ion, which is capable of 
forming adducts with protein amino groups, particularly lysine (Figure 4) (Sabbioni et 
al. 1987). The dihydrodiol/dialdehyde equilibrium is complex and both forms are 
present at physiological pH (Guengerich et al. 2002). 
 
AFB1 dihydrodiol  AFB1 dialdehyde 
 
Figure 4: Reaction of AFB1 dialdehyde with lysine to form the aflatoxin B1-lysine 
adduct (Guengerich et al. 2002). 
 
AFB1 exo-epoxide, is the only known genotoxic product of AFB1 (Wang and Groopman 
1999). When added to DNA or guanosine containing double-stranded 
oligodeoxynucleotides, it readily adducts the N7 position of guanine by covalent binding 
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to C8 of AFB1 epoxide (Johnson and Guengerich 1997). This reaction yields the 
predominant AFB1–DNA adduct identified as trans-8,9-dihydro-8-(N7-guanyl)-9-
hydroxy-AFB1 (AFB1-N7-guanine) (Figure 5) (Essigmann et al. 1977). 
 
 
 
 
 
 
 
Figure 5: Aflatoxin B1- N7-guanine 
 
AFB1-N7-guanine comprises over 95% of all AFB1-DNA adducts (Iyer et al. 1994). The 
presence of adducts creates a positive charge in the imidazole ring of guanine, which 
results in one of the two alternatives: 1) the majority of the AFB1-N7-Gua adducts are 
removed from DNA rapidly as they are relatively unstable within the DNA structure 
and are excreted exclusively into urine, having a half life of 7.5 hours (Wang and 
Groopman 1999), 2) a chemical rearrangement occurs resulting in the imidazole ring 
opening to form an AFB1-formamidopyrimidine structure (AFB1-FAPY) (Lin et al. 
1977) (Figure 6). 
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Figure 6: Pathway of metabolic AFB1 activation leading to AFB1-N7-guanine adduct 
formation. This adduct has a destabilized glycosidic bond and either depurinates to form 
an apurinic site in the DNA or undergoes opening of its imidazole ring, giving rise to 
the chemically and biologically stable formamidopyrimidine adduct (AFB1-FAPY) 
(Smela et al. 2001). 
 
 
CYP 3A4 and 1A2 also oxidize AFB1 to various other derivatives than epoxides, the 
major ones being the hydroxylated metabolites of AFM1, aflatoxin Q1 (AFQ1) and the 
demethylation metabolite of aflatoxin P1 (AFP1) (Figure 7). 
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Figure 7: The structure of aflatoxin M1, Q1 and P1; hydroxylated metabolites of 
aflatoxin B1. 
 
 
AFM1 appears to be formed preferentially by CYP 1A2 and AFQ1 mainly by CYP 3A4 
(Raney et al. 1992). AFM1 is the major aflatoxin metabolite in humans (Groopman et 
al. 1985). AFM1 can be further activated to form an AFM1-8,9-epoxide that binds to 
DNA and is excreted into urine in the form of AFM1-N7-guanine (Egner et al. 2003). 
AFQ1 and AFP1 are not appreciably oxidized by human liver microsomes and are not 
very genotoxic (Raney et al. 1992). Generally, the hydroxylated AFB1 metabolites 
(AFM1, AFQ1, AFP1), are poorer substrates for epoxidation and have reduced 
genotoxicity compared to AFB1. Thus they are generally considered as detoxification 
products. However, in the case of AFM1, the reported high cytotoxicity of the 
compound (Neal et al. 1998) highlights the caution that needs to be exercised in 
designating the formation of AFM1 as detoxification product. 
The formation of one further metabolite, aflatoxicol, a reduced aflatoxin species, has 
also been shown and it is reported to have an equal potency to AFB1 as a carcinogen 
(Coulombe et al. 1982). 
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Phase II conjugation reactions (detoxification) 
Phase II reactions consist of enzymatic reactions that conjugate the modified xenobiotic 
with another substance e.g. with glucuronic acid or glutathione. The conjugated 
products are larger molecules than the substrate and are generally polar in nature (water-
soluble) and thus, they can be readily excreted from the body. 
In the case of AFB1, detoxification is accomplished by enzymatic conjugation of the 
hydroxylated metabolites with glucuronic acid to form water soluble glucuronide esters 
that are excreted in urine or bile. Additionally, AFB1 in the epoxide form can be 
conjugated to glutathione (GSH) and subsequently be excreted in the bile (Busby and 
Wogan 1984). 
The conjugation of the epoxide to GSH is catalyzed by the cytosolic glutathione-S-
transferases (GST) (Neal et al. 1987). These transferases play a significant role in the 
detoxification of AFB1 epoxide and in the species susceptibility to the toxic effects of 
AFB1. The most striking species difference has been observed between the mouse and 
the rat. Although the mouse has very high microsomal epoxidation activity, it is very 
resistant to AFB1-induced tumors in comparison to the rat, which is a sensitive species. 
The conjugation of GSH to the AFB1 epoxide has been shown to be higher in the mouse 
than in the rat, and the very high level of GST activity towards AFB1 epoxide in the 
mouse appears to be the basis of the resistance of this species (Eaton et al. 1994). 
Glucuronidation of the hydroxylated AFB1 metabolites by UDP-glucuronyl transferases 
is another reaction for the elimination of the metabolites from the body. However, 
AFM1, since it is a tertiary alcohol (the C-OH carbon is bonded to 3 carbons), is not a 
good substrate for glucuronidation (Busby and Wogan 1984). Glucuronic acid 
conjugates are primarily eliminated via the bile, thus the enterohepatic circulation could 
prolong the effective half-life of AFB1. Figure 8 summarizes the known pathways 
involved in AFB1 metabolism. 
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Figure 8. AFB1 elimination in humans: a schematic diagram for the known pathways of 
AFB1 metabolism in humans and possible routes of excretion of different AFB1 
metabolites (modified from Eaton et al. (2001) and Wild and Turner (2002)). 
 
aExtensive human and experimental evidence on excretion of this metabolite; bScant or no 
evidence available; cOnly experimental evidence available (no human data). 
GST = glutathione S-transferases; mEH = microsomal epoxide hydrolase; AFAR = aflatoxin 
B1-aldehyde reductase. 
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2.2.4. Excretion 
AFB1 and its metabolites are excreted primarily through the fecal and urinary routes 
(Figure 8). In the case of lactating mothers, aflatoxin metabolites are also excreted in 
breast milk after consumption of aflatoxin contaminated food. 
 
Fecal excretion 
Aflatoxins are excreted in the feces in two ways, excretion of the unabsorbed aflatoxin 
from the lumen of the gastrointestinal tract and biliary excretion to the intestine. The 
biliary route is the major route of excretion of the absorbed aflatoxins and their 
metabolites. AFB1-GSH, which is a stable, non toxic, polar product, together with 
glucuronidated aflatoxin metabolites, is excreted from the liver via the bile into the 
gastrointestinal tract. Subsequently, these metabolites will either be excreted by the 
fecal route or metabolized by enzymes in the intestinal microbiota capable of 
hydrolyzing some glucuronide conjugates which then release the aflatoxins that may 
then be reabsorbed by the gastrointestinal tract (enterohepatic circulation) (Hsieh and 
Wong 1994). 
 
Urinary excretion 
The urinary excretion is an important route of excretion of absorbed aflatoxins and their 
metabolites. AFM1, AFQ1, AFP1 (Groopman et al. 1985, Egner et al. 2003) and AFB1-
N7-guanine (Essigmann et al. 1982, Groopman et al. 1992a) are excreted through the 
urinary route. The AFB1-GSH metabolite undergoes sequential metabolism in the liver 
and kidneys to form mercapturic acid conjugates (aflatoxin-N-acetylcysteine) also 
excreted in the urine (Scholl et al. 1997). The glucuronidated aflatoxin metabolites can 
be excreted both by biliary and urinary routes, the former being the primary route of 
excretion (Hsieh and Wong 1994). 
In many animal species (rats, sheep, pigs, cows), AFM1 is the main unconjugated AFB1 
metabolite in the urine and accounts for 2-9% of the dose (IARC 1993). AFM1 is also 
the major urinary aflatoxin metabolite in human subjects exposed to dietary AFB1 (Zhu 
et al. 1987). Only small amounts, between 1.2 and 2.2% of dietary AFB1, have been 
shown to be present in the urine as AFM1 (Zhu et al. 1987), and 0.2% of the AFB1 was 
calculated to be excreted in urine as AFB1-N7-guanine (Groopman et al. 1992c). 
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Excretion in milk 
The presence of aflatoxins in breast milk provides the main source of aflatoxin for 
newborn infants. Milk synthesis in the mammary gland cells is under hormonal control, 
promoted by the increasing serum prolactin levels occurring shortly after delivery. Milk 
production is regulated and adjusted by the infant’s demands and therefore normally 
increases gradually during the lactation period. Furthermore, milk production is 
influenced by a variety of factors including age, stress, nutritional and health status of 
the mother (Jensen and Slorach 1991). 
The composition of the breast milk varies strongly with time of lactation. Milk volume 
and concentrations of fat, lactose and water-soluble vitamins increase, while those of 
proteins, fat-soluble vitamins, phospholipids and cholesterol decrease from the first 
postpartum week’s breast milk (colostrum) to the mature milk (Lawrence 1999). 
Some of the components in the human milk are formed through synthesis in the breast 
gland itself, e.g. most proteins, lactose and triglycerides. Other compounds are 
transferred from the blood, e.g. vitamins, fatty acids and minerals. In the latter case the 
concentration may be higher than that in the blood, and the components are then 
transported by an active process through the epithelial cells to the milk duct lumen 
(Jensen and Slorach 1991). 
The excretion of a chemical into breast milk and the amount of the chemical that passes 
into the milk is affected by many factors that can be divided into chemical and 
physiological/maternal characteristics. The chemical characteristics refer to those 
aspects of the compound that affect its ability to be taken up in milk, such as lipid 
solubility, degree of ionization, molecular weight, and ability to bind to maternal blood 
and/or milk components (Clewell and Gearhart 2002). The physiological/maternal 
characteristics can be separated into external (dietary and environmental exposure) and 
internal factors (maternal age and body weight, parity, length of lactation, fat 
mobilization and fat concentration in milk) (Harris et al. 2001, Clewell and Gearhart 
2002). The most critical factor determining the chemical dose delivered to the infant is 
obviously the extent and pattern of maternal exposure (Clewell and Gearhart 2002). 
AFM1 is the primary aflatoxin metabolite in both animals and human milk, comprising 
95 % of the total amount of aflatoxins excreted in milk. It has been estimated that 0.09–
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0.43% of dietary intake is excreted in the human milk as AFM1 (Zarba et al. 1992). The 
factors affecting the excretion of AFM1 in human milk have not been studied in detail 
and therefore very little information is available. Many animal studies have been 
performed on the excretion of AFM1 in milk as a result of AFB1 exposures, but they 
have mainly focused on the extent of conversion of AFB1 to AFM1. The carry-over 
values of AFB1 from feed into AFM1 in milk in dairy cattle or sheep vary from 0.3 to 
6.2 % (Patterson et al. 1980, Veldman et al. 1992, Battacone et al. 2005). The 
concentrations of aflatoxin M1 in milk appear to vary widely from animal to animal, 
from day to day, even from one milking to the next (Van Egmond 1994). 
AFM1 can be found in milk within 12–24 h after the first ingestion of AFB1 (Battacone 
et al. 2003) and it is found up to three to seven days after last ingestion of the 
mycotoxin. The carry-over (percentage) of AFM1 in milk is not dependent on the 
dosage of AFB1. The levels of AFM1 in the milk however, are significantly influenced 
by AFB1 dosage (Battacone et al. 2003). 
Veldman et al. (1992), conducted a study in which dairy cows in the early lactation 
stage (2-4 weeks) and dairy cows in late lactation weeks (34-36 weeks) were fed daily 
AFB1 contaminated feed. After 12 days, the carry-over of AFM1 in the milk was 6.2% 
in the early stage, but it declined to 1.8% in the late lactation stage. 
 
2.3. Methods of assessing exposure to aflatoxins 
 
It is extremely difficult to obtain an accurate estimation of individual aflatoxin exposure 
by conventional epidemiological approaches based on questionnaires estimating food 
intake. This is mainly due to the minute aflatoxin quantity in foodstuffs, the striking 
daily and seasonal variations, and the practical difficulties in assessing food intake in 
rural agricultural societies where aflatoxin exposure is more of a problem (Hall and 
Wild 1994, Chen and Chen 2002). Molecular dosimetry methods have been used to 
develop biomarkers to quantify the biologically effective dose of aflatoxin exposure. 
The following sections will review briefly the different methods of assessment of 
individual aflatoxin exposures: the use of questionnaires and their limitations, and the 
application of biomarker measurements in human biological fluids. 
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2.3.1. Dietary questionnaires in aflatoxin exposure assessments 
Human exposure to aflatoxins has been assessed in the context of conventional 
epidemiological studies in two ways: either by the use of questionnaires estimating 
quantity and frequency of intake of dietary items assumed to be commonly 
contaminated with aflatoxin, or by a combination of questionnaire and laboratory 
measurements on representative food samples collected from the population concerned. 
The limitations by either of these two approaches are summarized below: 
Firstly, aflatoxin contamination of foods is extremely variable and estimation of 
aflatoxin levels in foods may be difficult. Efforts have been made to achieve reliable 
sampling and a review of sample preparation methods was published by the AOAC 
International (Scott 1990). However, estimates on human exposure based on food 
analysis can easily lead to misclassification of individuals with respect to exposure (Hall 
and Wild 1994). Misclassification of exposure status is claimed to be a major 
contributor to the insensitivity of many epidemiological investigations (Groopman and 
Kensler 1999). 
Second, an additional confounding factor is the marked seasonal variation in aflatoxin 
levels (Wild et al. 2000), reflecting both climatic changes and food harvesting and 
storage practices. High temperature and humidity in the wet and hot seasons increase 
the likelihood that the Aspergillus fungi will grow on the crop, resulting in higher 
aflatoxin contamination. Initially after harvest, the levels of AFB1 in foodstuffs are 
expected to be low. However, as the food is stored for longer periods, the likelihood of 
Aspergillus contamination increases as does the potential level of AFB1 (Hall and Wild 
1994). 
Third, the exposure linked to a disease outcome may have happened at a different time 
than the measurements of the food intake, perhaps even months or years apart. In 
addition, the development of a disease may affect the diet and thus food intake 
measurements of diseased individuals may be misleading. Furthermore, the actual 
recording of food intakes may also lead to abnormal eating behaviors (Hall and Wild 
1994). 
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Finally, there are practical difficulties in assessing food intake in rural agricultural 
societies where aflatoxin exposure mostly occurs (Qian et al. 1994, Groopman et al, 
1992a). Measurements of individual portions may be challenging when individuals eat 
from a common food bowl either by hand or with a spoon, or as is the case in groundnut 
producing societies, where they consume nuts throughout the entire day. 
In view of these limitations, the preferable method for allowing individual exposure 
evaluation is that of biomarker assessment and thus measurement of biomarkers in 
human biological fluids has been used increasingly to confirm and quantify exposure to 
aflatoxins (Wild and Hall 1994). 
 
2.3.2. Biomarkers of aflatoxin exposure 
Biomarkers in general 
Biomarkers are a measure of a cellular, biochemical or molecular change in biological 
media (human tissues, cells or fluids), which is informative with respect to assessing an 
exposure, or a change relevant to a disease pathway indicating the presence or extent of 
a disease (Groopman 1994). Biomarkers are used to indicate or measure a biological 
process, and therefore the detection of biomarkers specific to a disease can aid in the 
identification, diagnosis, and treatment of affected individuals who may be at risk but 
do not yet exhibit symptoms. 
The main goals of biomarker research are to develop and validate chemical-specific 
biomarkers that reflect specific exposures and predict disease risks in individuals, to 
provide an objective measure for determining the effectiveness of interventions to lower 
exposure and risks, and to clarify the interactions of multiple agents and multiple 
exposures and their relation to disease outcomes (Groopman and Kensler 1999). 
The distinct steps in the progressive nature of many chronic diseases and the alterations 
in the molecular mechanisms underlying the association between exposure and disease 
facilitate the development of biomarkers. 
The biomarkers can be classified into those reflecting susceptibility, internal dose, 
biologically effective dose, early biological effect, altered structure/ function and 
clinical disease (Figure 9). 
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Figure 9: Classification of biomarkers (Groopman and Kensler 1999). 
 
 
Internal dose is the amount of material which is internalised into the body and 
metabolised. The level of this dose may be subject to interindividual variation through 
differences in metabolism, activation and/or detoxification of a compound. The 
biologically effective dose is the dose that reaches the target tissue and produces an 
effect. Certain changes are termed as early biological effects e.g. increased proliferation, 
somatic cell mutations, genetic alterations that result in altered cell structure and 
function. A range of factors within the individual determine its susceptibility to the 
exposure, e.g. the ability to activate/detoxify carcinogens, the ability to repair DNA 
damage, its nutritional and immune status, age, sex, socio-economic status (WHO 
1993). 
The biomarkers can be also categorized as biomarkers of exposure, effect and 
susceptibility. Biomarkers of exposure indicate the exposure to the parent compound, 
the biomarkers of effect signal biological responses to an exposure and the biomarkers 
of susceptibility provide information about the inherent sensitivity of a person to an 
environmental agent, as mentioned above (WHO 1993, Groopman 1994). 
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Biomarkers of aflatoxin exposure 
An understanding of the mechanisms of aflatoxin actions provides a rationale for using 
some of the aflatoxin metabolites found in urine or blood as biomarkers of aflatoxin 
exposure and effect (Wild and Turner 2002). The use of aflatoxin metabolites as 
biomarkers reflects not only the dietary exposure of the individual but also the 
characteristics of that individual with respect to the uptake, distribution, metabolism, 
detoxification and removal of aflatoxin adducts. This double contribution is a key point 
to consider when interpreting the data obtained in epidemiological studies (Wild and 
Pisani 1998). 
Biomarkers of aflatoxin exposure and effect have been validated in detail in studies in 
experimental animals and humans. Dose-response relationships between biomarker 
levels and liver tumor incidence were first established in experimental animals 
(Groopman et al. 1992b). The biomarkers were then used in pilot studies in humans to 
define the sensitivity, specificity, accuracy, and reliability parameters. Further 
validation in transitional epidemiological studies assessed intra and inter-individual 
variability, background levels, external dose-marker relationship, and the feasibility of 
use in larger population based studies (Groopman et al. 1992a, 1992c). Finally 
prospective epidemiological studies were conducted to evaluate biomarker effectiveness 
in identifying the risk of developing hepatocellular carcinoma (HCC) associated with 
aflatoxin exposure (Qian et al. 1994, Sun et al. 1999). Currently, the most detailed 
epidemiological description linking a certain DNA adduct to development of a 
particular form of cancer exists for AFB1 (Sharma and Farmer 2004). Few carcinogens 
have undergone such extensive validation. In fact these studies can be viewed as 
providing a model for the development, validation and application of chemical-specific 
biomarkers for evaluating the molecular epidemiology of other cancers in which 
environmental carcinogens are thought to play etiologic roles (Wogan 2000). 
Biomarkers of aflatoxin exposure have been used in studies of the etiology of HCC, in 
assessments of the role of polymorphism in aflatoxin metabolizing enzymes and the 
altered levels of metabolite formation in some individuals, and in the assessments of the 
effect of DNA repair enzyme polymorphisms on the levels of AFB1-N7-guanine adducts 
(Wild and Turner 2002). 
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Detection of aflatoxins in human biological fluids 
Biomarkers of aflatoxin exposure include urinary aflatoxin metabolites, such as AFB1-
N7-guanine and AFM1, serum AF-albumin (Wild and Turner 2002), and AFM1 in milk 
(Van Egmond 1994). 
AFM1 is the major unconjugated urinary aflatoxin metabolite in humans (Groopman et 
al. 1985). Numerous observational reports of the presence of AFM1 and other 
metabolites in urine are available reflecting aflatoxin exposure (Table 2). Zhu et al 
(1987) analyzed 252 urine samples from 32 households from the Guangxi region in 
China and reported a good correlation between total dietary AFB1 intake and AFM1 
excretion. Between 1.2 and 2.2% of dietary AFB1 was present as AFM1 in the urine. 
Groopman et al (Groopman et al. 1992c) analyzed the same urine samples, confirmed 
the findings on AFM1 and also demonstrated the presence of AFB1, AFQ1, AFP1 and 
AFB1-N7-guanine in urine. In that study also the levels of AFB1-N7-guanine adducts 
were correlated with AFB1 intake. The percentage of AFB1 excreted as the above 
metabolites was 4.4% in women and 7.6% in men. 
The levels of AFB1-N7-guanine adducts in urine (Groopman et al. 1992a, 1992c) and 
AF-albumin adducts in the blood (Gan et al. 1988, Wild et al. 1992) reflect the 
biologically effective aflatoxin dose to which an individual has been exposed and they 
are both well validated as biomarkers of exposure. Gan et al. (1988) showed that the 
level of AF-albumin adducts in the blood were correlated not only with the dietary 
intake of AFB1, but also with the urinary excretion of AFM1 in individuals. Wild et al. 
(1992) confirmed the validity of AF-albumin adducts as a biomarker of aflatoxin 
exposure, and Groopman et al (Groopman et al. 1992c, 1994) demonstrated a 
correlation between the levels of serum AF-albumin adduct and urinary AFB1-N7-
guanine adduct. Urinary AFB1-N7-guanine adducts reflect dietary exposure over the 
previous 1-2 days (Groopman et al. 1992a, 1992c), while the level of AF-albumin 
adduct in serum reflects exposure over the previous 2-3 months (Wild et al. 1992). It 
has been estimated that 1.4-2.3% of ingested AFB1 is covalently bound to albumin (Gan 
et al. 1988) and 0.2% of the AFB1 is excreted as AFB1-N7-guanine in urine (Groopman 
et al. 1992c). An AFG1-albumin adduct has also been identified (Sabbioni and Wild 
1991). 
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Table 2: Aflatoxins and their metabolites in human biological fluids. 
Level* Sample Country Aflatoxins 
and metabolites 
n of  
subjects 
% positive 
 samples mean range 
Reference 
Urine China AFM1 145 54 NS§ ng/ml 0.003-
0.243 
(Sun et al. 
1999) 
Urine China AFM1 42 NS§ 930 ng/ml NS§ 
NS§ ng/day 
0.01-3.2 
40-4800  
(Zhu et al. 
1987) 
Urine China AFM1 
AFB1-N7-Gua 
AFB-mercapturate 
AFQ1 
AFP1 
29 89 
41 
89 
26 
30 
192 ng/day 
407 
103 
92.2 
664 
0.9-3569 
64.9-1789 
6.6-494 
77.3-137 
80.4-3569 
(Wang et al. 
2001) 
Urine China AFM1 
AFB1-N7-Gua 
AFP1 
AFB1 
317 
 
67 
49 
53 
71 
NS§ ng/ml 
NS§ 
NS§ 
NS§ 
0.17-5.2 
0.3-1.81 
0.59-16 
NS§ 
(Qian et al. 
1994) 
Urine China Total aflatoxins 
(AFB1-N7-Gua, 
AFB1, AFQ1, AFP1) 
42 NS§ NS§ ng**/ml 
NS§ ng**/day 
1.5-2.3 
3300-6600 
(Groopman et 
al. 1992c) 
Urine Gambia AFB1-N7-Gua 
(AFG1, AFM1, AFP1, 
AFQ1 also detected) 
20 NS§ NS§ ng/day 48.2-7099 (Groopman et 
al. 1992a) 
Urine Egypt AFB1 
AFM1 
AFG1 
20 30 NS§ ng/ml 
NS§ 
1.1## 
<1.5 
<2.5 
- 
(Al-Saadany 
1993) 
Urine Egypt AFB1 60 61 NS§ ng/ml 0.01-0.15 (Hatem et al. 
2005) 
Blood Egypt AFB1 60 61 NS§ ng/ml 0.04-0.69 (Hatem et al. 
2005) 
Blood Egypt AFB1 
AFM1 
AFM2 
20 55 NS§ ng/ml 
NS§ 
0.2## 
<4.5 
<0.5 
- 
(Al-Saadany 
1993) 
Blood China AF-alb 42 NS§ NS§ pg/mg^ 30-340 (Gan et al. 
1988) 
Blood Gambia AF-alb 20 NS§ 44 pg /mg^^ NS§ (Wild et al. 
1992) 
Blood Gambia 
Feb/March 
July/Aug 
AF-alb 357 100  
83.2 pg/mg^ 
34.9 pg/mg^ 
 
NS§ 
(Wild et al. 
2000) 
Blood Gambia AF-alb 444 100 NS§ pg/mg^ 2.2-459 (Turner et al. 
2000) 
Blood Gambia AF-alb 117 100 29.3 pg/mg^ 2.2-250.4 (Wild et al. 
1993) 
Blood Guinea AF-alb 124 96 9.9 pg/mg^ NS§ (Turner et al. 
2005b) 
Blood Guinea AF-alb 600 95 NS§ pg/mg^^^ 9.4-22 (Sylla et al. 
1999) 
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Table 2: Aflatoxins and their metabolites in human biological fluids. Continued. 
Sample Country Aflatoxins 
and metabolites 
n of  
subjects 
% positive 
 samples 
Level* Reference 
Blood Benin AF-alb 480 99 NS§ pg/mg^ 5-1064 (Gong et al. 
2002) 
Breast 
milk 
United Arab 
Emirates 
AFM1 140 92 560# pg/ml 5-3400 (Abdulrazzaq 
et al. 2003) 
Breast 
milk 
United Arab 
Emirates 
AFM1 445 100 NS§pg/ml 1.7-3000 (Saad et al. 
1995) 
Breast 
milk 
Australia 
Thailand 
AFM1 73 
11 
15 
44 
71# pg/ml 
664# pg/ml 
28-1031 
39-1736 
(El-Nezami et 
al. 1995) 
Breast 
milk 
Egypt AFM1 
AFG1 
(AFB1, AFB2, 
AFG2 also 
detected) 
200 11 160 pg/ml 
NS§ pg/ml 
120-200 
38-47 
(El-Shewey 
1992) 
Breast 
milk 
Gambia AFM1 5 100 NS§ pg/ml ≤ 1.4 (Zarba et al. 
1992) 
Breast 
milk 
Ghana AFM1 264 22 NS§ pg/ml 20-1816 (Lamplugh et 
al. 1988) 
Breast 
milk 
Zimbabwe AFM1 54 11 NS§ pg/ml 14-50  (Wild et al. 
1987) 
Breast 
milk 
Sudan AFM1 99 23 NS§ pg/ml 5-64 (Coulter et al. 
1984) 
Cord 
blood 
United Arab 
Emirates 
AFM1, 
AFM2,AFB1 also 
201 53 
 
1229# pg/ml 110-4060 (Abdulrazzaq 
et al. 2002) 
Cord 
blood 
Thailand Total aflatoxins 
(AFB1, AFQ1, 
AFG1) 
35 48 3.1 nmol/ml 0.064-13.6 (Denning et al. 
1990) 
Cord 
blood 
Gambia AF-alb 30 97 NS§pg/mg 5-30 (Wild et al. 
1991) 
*The levels are presented in comparable units whenever possible. The presented means for the 
AF-albumin adducts are geometric means, §not specified 
**AFB1 equivalents, ^pg AFB-alb/mg albumin, ^^this is an arithmetic mean 
^^^this is the range of geometric means from 8 different villages in Guinea 
#This is a median, ##only one positive sample 
 
 
AFM1 is excreted also in breast milk during lactation. Several studies have 
demonstrated the presence of AFM1 in human milk (Table 2). For example, in the 
United Arab Emirates, AFM1 was detected in milk at levels of 5-3400 pg/ml 
(Abdulrazzaq et al. 2003), in Victoria, Australia in the range 28-1031 pg/ml, and from 
39 to 1736 pg/ml in Thailand (El-Nezami et al. 1995). In one report of five lactating 
women in the Gambia (Zarba et al. 1992), 0.09-0.43% of dietary intake was excreted in 
the milk as AFM1. 
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Aflatoxins have also been detected in umbilical cord blood samples demonstrating that 
aflatoxin can cross the placenta barrier and exposure to these carcinogens can start 
already in utero (Wild et al. 1991). 
 
2.4. Aflatoxins and health effects 
 
Aflatoxins are toxic, carcinogenic and mutagenic in humans and animals and AFB1, the 
most prevalent and potent form of the aflatoxins, has been classified as a class 1A 
human carcinogen by the IARC (1993). Recently, aflatoxins have been strongly 
associated also with early childhood growth faltering (Gong et al. 2003, Turner et al. 
2003, Gong et al. 2004) and reduced levels of salivary IgA (Turner et al. 2003). 
Susceptibility to aflatoxins is greater in the young (Williams et al. 2004), and aflatoxin 
exposure can start in utero (Wild et al. 1991) and continue throughout early infancy and 
childhood. AFM1 provides a source of aflatoxin exposure to the lactating infant (Wild et 
al. 1987, Zarba et al. 1992, El-Nezami et al. 1995), and thereafter the level of exposure 
increases significantly with the introduction of adult foods after weaning (Gong et al. 
2003, 2004). AFM1 has cytotoxic properties in human hepatocytes (Neal et al. 1998) 
that may have important implications for immunocompetence and growth. This section 
will address the main health problems associated with human aflatoxin exposure. 
 
2.4.1. Toxicity of aflatoxins 
Aflatoxicosis is the poisoning that results from ingesting aflatoxins. Two forms of 
aflatoxicosis have been identified: 1) acute severe intoxication which results in direct 
liver damage and subsequent illness or death, and 2) chronic sub-symptomatic exposure 
that has nutritional and immunological consequences. All doses of exposure are 
considered to have a cumulative effect on the risk of cancer. 
The order of potency for both acute and chronic toxicity of aflatoxins is AFB1> AFG1> 
AFB2> AFG2 (IARC 1993). In ducklings and rats, the toxicity of AFM1 was similar or 
slightly less than that of AFB1 (JEFCA 1998). Although AFM1 can be activated to form 
AFM1-8,9-epoxide as shown from recent studies on the urinary AFM1-N7-guanine 
excretion of tree shrews and rats (Egner et al. 2003), metabolic epoxidation is not 
necessary for AFM1 to exert cytotoxicity as demonstrated by the results of in vitro 
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studies (Neal et al. 1998), where AFM1 was directly toxic in the absence of metabolic 
activation compared to AFB1. While it is widely accepted that both the carcinogenic and 
acutely toxic responses of AFB1 are dependent on metabolic activation, the role of 
metabolism in the cytotoxicity of AFM1 is unclear. 
The liver is usually the target organ for both acute and chronic aflatoxin toxicity, but 
lesions in the kidney and stomach have also been reported in rats (IARC 1993). 
The differences in susceptibility to aflatoxins across species and between persons 
depend largely on the fraction of the dose that is directed into the various possible 
metabolic pathways, with harmful biological exposure being the result of activation to 
the epoxide and the reaction of the epoxide with proteins (Figure 10). 
 
 
Figure 10. Pathways and consequences of aflatoxin metabolism (Williams et al. 2004). 
 
Acute toxicity 
The symptoms of severe aflatoxicosis include fever, edema, lethargy, vomiting, 
abdominal pain, and potentially fatal liver failure. In animal experiments, rabbits, ducks 
and pigs are more susceptible species with a low median lethal dose (0.3-0.6 mg/kg 
body weight), whereas Fisher rats (2 mg/kg body weight), chickens (18 mg/kg body 
weight), and mice 15 mg/kg body weight) display greater tolerance. Adult humans 
usually have a high tolerance to aflatoxin, and in the reported acute poisonings, it is 
usually the children who are affected and die (Williams et al. 2004). 
Reported incidents of acute human aflatoxin poisonings are relatively infrequent, 
probably because people usually avoid eating obviously mouldy foods. However, in 
conditions of poverty and food shortages, then people have no option but to use any 
available food irrespective of quality. 
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Reports of death and serious illnesses usually originate from the developing countries 
that are the countries at risk (Table 3). An early case report linked fatal hepatic toxicity 
of a 15- year-old boy to consumption of mouldy cassava and subsequent analysis of the 
mouldy cassava in the family’s store revealed that it had a high aflatoxin content (1.7 
mg/kg) (Serck-Hanssen 1970). More recently, an acute aflatoxicosis outbreak was 
reported in young adults in Kenya (Barrett 2005). The outbreak followed a poor harvest 
of maize that had been damaged and rendered susceptible to mold by drought. 
Furthermore, to guard the inadequate harvest against theft, the people stored the maize 
in their homes, which were warmer and more damp than the centralized granaries where 
maize was usually stored. From January to June 2004, 317 people sought hospital 
treatment for the symptoms of liver failure, and 125 of them died. Health officials 
examined maize samples and found AFB1 concentrations as high as 4.4 mg/kg, which is 
220 times the Kenyan limit for aflatoxin in foods. In Kenya, a previous outbreak of 
jaundice accompanied by fatalities, was also associated with the consumption of maize 
that contained up to 12 mg/kg AFB1 (Ngindu et al. 1982). 
In 1988, 13 Chinese children died of acute hepatic encephalopathy (brain and nervous 
system damage that occurs as a complication of liver disorders) as a result of severe 
aflatoxicosis (Chao et al. 1991, Lye et al. 1995). The disease was described to cause 
symptoms similar to Reye’s syndrome. Reye's syndrome primarily targets the brain and 
liver, and the symptoms involve drowsiness, confusion, seizures, coma, and in severe 
cases, death. It is a rare but serious disease that most often affects children 6 to 12 years 
of age and it seems to be related to the use of aspirin to treat some viral illnesses, such 
as chickenpox. 
A number of case reports linking AFB1 to Reye's syndrome exist in the literature. 
Although Reye’s syndrome occurs throughout the world and there is no apparent 
geographical association with aflatoxin exposure, the disease has been associated with 
aflatoxins because AFB1 has been detected in Reye’s syndrome patients in New Zealand 
(Becroft 1966), Thailand (Shank et al. 1971), the former Czechoslovakia (Dvorackova 
et al. 1977), and the United States (Ryan et al. 1979). The accumulation of aflatoxin in 
these cases however, could be a result of the disease affecting metabolism rather than an 
etiological factor (Hall and Wild 1994). 
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Table 3: Outbreaks of aflatoxicosis and aflatoxin association with Reye’s syndrome 
Country Number 
of 
subjects/ 
deaths 
Symptoms Source and 
level of 
exposure 
Aflatoxins in biological 
samples and post-mortem 
liver  examinations 
Reference 
Kenya 317/125 vomiting, abdominal 
pain, fatal liver 
failure 
Maize, AFB1 
4.4 mg/kg 
AF-alb in blood (Barrett 2005) 
Malaysia -/13 Vomiting, diarrhoea, 
abdominal pain, 
anorexia, seizures, 
and eventual coma. 
Iniatially many 
presented with a 
Reye like syndrome 
(hepatic 
encephalopathy) 
Chinese 
noodles 
Necrosis of the liver, giant 
cell formation, central vein 
sclerosis, bile stasis, and 
steatosis. Presence of acute 
tubular necrosis, superficial 
upper gastrointestinal 
erosions, and ensuing 
encephalopathy. The 
eventual cause of death was 
acute hepatic and renal 
failure. 
(Chao et al. 
1991) 
(Lye et al. 1995) 
Kenya 20/12 Vomiting, abdominal 
discomfort, anorexia, 
jaundice, leg edema, 
tachycardia, liver 
tenderness, 
gastrointestinal 
bleeding 
Maize, AFB1 
3.2-12 
mg/kg, 
AFB2 1.6-
2.7 mg/kg 
AFB1 in liver (autopsy), 
centrilobular necrosis, fatty 
infiltration 
(Ngindu et al. 
1982) 
India 994/97 Fever, jaundice, 
hepatomegaly, 
splenomegaly 
Maize, AFB1 
0.01-1.1 
mg/kg 
AFB1 in serum  (Tandon et al. 
1978) 
India 397/106 Vomiting, anorexia, 
jaundice, leg edema, 
gastrointestinal 
bleeding 
Maize, AFB1 
6.25- 15.6 
mg/kg 
Bile duct proliferation and 
giant liver cells 
(Krishnamachari 
et al. 1975) 
Uganda 1/1 Abdominal pain, leg 
edema, palpable liver  
Cassava, 
AFB1 1.7 
mg/kg 
Centrilobular necrosis, fatty 
changes 
(Serck-Hanssen 
1970) 
USA 7/7 Reye’s syndrome - AFB1 in blood and liver (Ryan et al. 
1979) 
Czecho-
slovakia 
27/27 Reye’s syndrome Aflatoxin 
contaminated 
milk food (5 
cases) 
AFB1 and AFM1 in liver, 
liver fatty degeneration, 
liver fibrosis with bile duct 
proliferation and steatosis, 
liver cirrhosis 
(Dvorackova et 
al. 1977) 
Thailand 23/23 Reye’s syndrome - AFB1 and AFB2 in brain, 
liver, kidney, stool (autopsy) 
(Shank et al. 
1971) 
New 
Zealand 
2/2 Reye’s syndrome - AFB1 in liver (autopsy)  (Becroft 1966) 
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Immunosuppressive effects 
AFB1 has been reported to affect both humoral and cell mediated immunity through the 
results on cell mediated immunity have been more consistent in studies conducted in 
poultry, pigs and rats (IARC 1993, Raisuddin et al. 1993, Williams et al. 2004). 
AFM1 has cytotoxic properties in human hepatocytes (Neal et al. 1998) that may have 
important implications for the effects of AFM1 on immunocompetence. In an in vitro 
study, AFM1 and AFB1 were particularly potent in reducing phagocytosis in rat 
peritoneal macrophages (Cusumano et al. 1995). 
There is limited evidence for any immunosuppressive effects of aflatoxins in humans. 
Turner et al (2003) examined whether aflatoxin exposure was associated with several 
immune parameters in a cross-sectional study of 478 Gambian children. In multivariable 
analysis, secretory immunoglobulin A (IgA) was lower in children with detectable AF-
albumin concentrations in comparison with those with non detectable concentrations. 
Additionally, the immune status of Ghanaian adults has been reported to be affected by 
aflatoxin exposure, with significant suppression of cellular immune system components 
when the adults with AF-albumin concentrations above the median were compared to 
those with concentrations below the median (Jiang et al. 2005). 
In animals, aflatoxin exposure has been also shown to modify the effectiveness of 
vaccination by reducing the antibody response to vaccines, a finding that is not 
surprising given the immunosuppressive effect of aflatoxins (Wild and Hall 2000). 
Considering the high morbidity and mortality from infectious diseases in the developing 
countries, an immunosuppressive effect of aflatoxins that would modulate susceptibility 
to infectious agents may be of major importance. 
 
Nutritional status and growth retardation 
Chronic exposure to aflatoxins has major effects on nutritional status and rate of growth 
in animals. The efficiency of food use is consistently less in animals that are exposed to 
aflatoxins compared to in those that are not exposed. In poultry and pigs, a 7-10% drop 
in food conversion efficiency has been observed, in fact decreased growth rates are 
often viewed as signs of chronic aflatoxin exposure (Shane 1994, Williams et al. 2004). 
Malformations and reduced fetal weight have been seen after mice were injected 
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intraperitoneally with high doses of aflatoxin. In rats, decreased pup weight and 
behavioral changes have been reported at low doses (IARC 2002). 
Recent studies suggest that these effects may also apply to humans, with aflatoxin 
exposure associated with growth impairment in young children (1-3 years). In a cross-
sectional study in Benin and Togo, young children showed a relationship between 
stunted growth and the level of AF-albumin in serum. This biomarker of aflatoxin 
exposure was detected in 99% of the children. The level of serum AF-albumin was 
strongly associated with growth faltering, particularly stunting (Gong et al. 2002, 2003). 
A longitudinal study in the same population confirmed the association between 
aflatoxin exposure and growth stunting (Gong et al. 2004). An association between AF-
albumin adduct level and wasting was also observed in a study in Gambian children 
(Turner et al. 2003). In that study, a negative correlation of AF-albumin levels with 
vitamin C concentrations in serum was also observed. 
Aflatoxin has also been suggested to be a factor modulating the rate of recovery from 
protein malnutrition (kwashiorkor) (Hendrickse 1997), and in a recent study of 60 
Egyptian infants, kwashiorkor strongly associated with both the serum and urinary 
aflatoxin levels (Hatem et al. 2005). In another study from Egypt it was reported that 
aflatoxins AFB1, AFG1 and AFM1, AFM2 were detected in blood of 11/20 (55 %) 
Egyptian children with kwashiorkor and urine samples of 6 children were aflatoxin 
positive (Al-Saadany 1993). However, aflatoxins have not been suggested to be 
responsible for the initiation of this condition (Househam and Hundt 1991). 
 
2.4.2. Mutagenicity and carcinogenicity 
Aflatoxins are among the most potent mutagenic and carcinogenic substances known 
(JEFCA 1998) and AFB1 has been classified as a class 1A human carcinogen by IARC 
(1993). 
Aflatoxin carcinogenicity has now been well established in many in vitro and animal 
experiments, and in addition, most of the epidemiological studies have provided 
sufficiently strong evidence for a correlation between AFB1 exposure and increased 
incidence of hepatocellular carcinoma (HCC) in individuals with a concomitant 
infection of hepatitis B virus (HBV) (Chen et al. 1997, Wild and Turner 2002). AFM1 
carcinogenicity is proven in animals, but as yet there are insufficient epidemiological 
 42 
data for AFM1 carcinogenicity to humans. Thus, IARC has classified AFM1 as a 
possible human carcinogen, group 2B (IARC 1993). 
In a study on weanling rats given either AFM1 or AFB1 by intubation, 3% of the rats 
given AFM1 developed HCC and 28% had pro-neoplastic lesions. All AFB1 fed rats 
developed tumours, while the controls showed no significant liver lesions (Wogan and 
Paglialunga 1974, Van Egmond 1994). In another study, rats were fed diets containing 
either AFB1 or different concentrations of AFM1. The highest AFM1 dose produced 
liver lesions in 15% of the rats and 5% developed HCC, while 95% of rats receiving a 
similar dose of AFB1 developed HCC. Some of the AFM1 fed rats developed intestinal 
carcinomas (Cullen et al. 1987). These and subsequent studies have indicated that the 
carcinogenic potency of AFM1 is one to two order of magnitude less than that of AFB1 
(Van Egmond 1994). Milk naturally contaminated with AFM1 produced fewer lesions 
than artificially contaminated milk, pointing to differences in the bioavailability of 
naturally and artificially occurring AFM1 (JEFCA 2000). 
A mutation is one possible consequence of binding of carcinogens to DNA, and it is a 
step in the carcinogenic process evoked by genotoxic carcinogens (Sharma and Farmer 
2004). The pathway of AFB1 metabolism that apparently accounts for its mutagenic 
effects is a consequence of the metabolic activation of AFB1 to the aflatoxin exo-
epoxide, the subsequent covalent reaction with DNA, predominantly with the formation 
of the AFB1-N7-guanine adduct. The formed adduct is relatively unstable within the 
DNA structure and it can lead to its release from the DNA giving rise to an apurinic 
DNA site, or to the formation of the chemically and biologically more stable AFB1-
formamidopyrimidine structure (AFB1-FAPY). 
The AFB1-N7-guanine, AFB1-FAPY and apurinic lesions are thought to be the 
precursors to the mutations induced by aflatoxin. Bailey et al (1996) assessed the level 
of aflatoxin induced mutations within Escherichia coli and indicated that AFB1-N7-
guanine gives rise to a significant proportion of the observed AFB1-induced mutations 
with the most frequently observed mutation induced to be a G to T transversion. Smela 
et al (2002) found that AFB1-FAPY caused a G to T mutation frequency in Escherichia 
coli approximately 6 times more often than that of AFB1-N7-guanine. Furthermore, the 
G to T transversion mutation in codon 249 of the p53 tumour suppressor gene was 
identified in HCC patients from regions of the world with high aflatoxin exposures 
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(Bressac et al. 1991, Hsu et al. 1991). Kirk et al. (2000) reported the same mutation in 
plasma DNA collected from HCC cases in Gambia. Turner et al. (2005b) reported the 
absence of the TP53 mutation of plasma DNA in young Guinean children with aflatoxin 
exposure, and noted that if the observation is representative of the true absence of TP53 
mutation in the liver, then the early childhood may provide a window in which 
intervention strategies may delay or reduce the incidence of HCC later in life. 
 
Synergistic interaction of aflatoxin and hepatitis B virus (HBV) in 
hepatocarcinogenesis. 
The chronic exposure to aflatoxins together with the chronic carriage of HBV are the 
two major risk factors involved in the multifactorial etiology of hepatocellular 
carcinoma (HCC) in countries with the highest incidence and the youngest patients with 
the disease (McGlynn et al. 2001, Kew 2003). Southeast Asia and sub-Saharan Africa 
have the highest incidences in HCC, are hyperendemic for HBV infection, and have 
high aflatoxin exposure prevalences. The rates of HBV positivity in Gambia, China and 
Guinea are 15%, 14-20% and 10%, respectively (Williams et al. 2004). In Egypt, 5.6% 
of the population are chronic carriers of HBV. In most countries hepatitis C virus 
(HCV) infection is about 1%, but in Egypt the prevalence of HCV is exceptionally high, 
reaching 20% in the general population. The annual prevalence of HCC in Egypt has 
increased significantly during the past decade (El-Zayadi et al. 2005). HCC is rapidly 
fatal with a survival rate after diagnosis of approximately one year. 
A striking synergistic interaction of aflatoxin exposure (based on urinary and blood 
biomarker measurements) and HBV in the risk of developing HCC has been revealed in 
large cohort studies carried out in Shanghai (Ross et al. 1992, Qian et al. 1994) and 
Taiwan (Wang et al. 1996) with a vast increase in the risk of HCC development when 
both risk factors were present (Table 4). 
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Table 4: Findings demonstrating the synergistic interaction between HBV infection and 
aflatoxin exposure in the risk of developing hepatocellular carcinoma (HCC). 
HBV alone AFB1 alone HBV and AFB1 Reference 
4.8 (1.2, 19.7) 1.9 (0.5-7.5) 60.1 (6.4-561.8) Ross et al, 1992 
7.3 (2.2, 24.4) 3.4 (1.1-10) 59.4 (15.6-212) Qian et al, 1994 
17.4 (3.6, 143.4) 0.3 (0-3.6) 70.0 (11.5-425.4) Wang et al 1996 
Values indicate the relative risk (95% confidence intervals) of developing hepatocellular cancer 
(HCC). 
 
A synergistic interaction of HCV and aflatoxins in the development of HCC in men 
with chronic HBV hepatitis has also been reported (Sun et al. 1999). The risk of HCC 
development in the subjects with detectable urinary AFM1 levels was 3.3-fold higher 
(95% CI: 1.2, 8.7) compared to controls. Co-infection with HCV increased the risk of 
HCC to 5.8 (95% CI: 2, 17). This study importantly added to the evidence that HCV can 
increase the risk of HCC in men with chronic HBV hepatitis. However, there were too 
few cases to demonstrate the effect conclusively. 
Thus, if one wishes to minimize the risk of developing HCC, it is important to minimize 
the aflatoxin exposure of HBV and HCV infected individuals. 
 
2.5. Methods for reduction of human aflatoxin exposure 
 
Strict food regulations are intended to minimize the aflatoxin exposure of populations in 
the developed countries, ensuring low levels of contamination in the produced/imported 
material. These control measures have failed in developing countries which often can be 
traced to inability to implement regulations, and even if there are restrictions, these 
often apply only to trade, resulting in exports of the higher quality materials leaving the 
low quality produce for local consumption (Williams et al. 2004). Therefore in the 
developing countries, economically feasible measures need to be considered to 
counteract the aflatoxin problem. 
Intervention strategies for aflatoxin exposure reduction are described as those applicable 
at the individual or at the community level (Wild and Hall 2000). At the community 
 45 
level, a reduction of exposure by limiting fungal contamination of crops can be 
addressed either as pre-harvest or post-harvest measures. At the individual level, dietary 
or post-ingestion interventions are considered (Figure 11). 
 
Figure 11: Approaches to primary prevention of hepatocellular carcinoma in 
developing countries (Wild and Hall 2000). 
 
2.5.1. Interventions at the community level 
Pre-harvest interventions involve measures aiming to reduce Aspergillus infection of 
crops and subsequent toxin production. Infestation of crops by Aspergillus most readily 
occurs under conditions of stress involving drought, high temperatures, insect induced 
injury or other processes which lead to damage of the crop. Therefore, appropriate pre-
harvest measures include improved irrigation, use of fungicides, pesticides and 
insecticides, genetic engineering of crops so that they are resistant to fungal infection or 
toxin biosynthesis, use of cereal strains resistant to fungal colonization, biocontrol by 
use of competitive non-aflatoxigenic Aspergillus strains. Nonetheless, many of these 
processes may not be economically feasible in high risk populations (Wild and Turner 
2002). 
Post-harvest measures focusing mostly on methods which could be applicable at the 
local farming level, ideally involve low technology approaches designed to inhibit 
further fungal growth and aflatoxin production in storage. The growth of Aspergillus 
post-harvest is influenced most critically by temperature, moisture content and storage 
time. Recently, a successful intervention based on harvest, drying, sorting, and storage 
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activities in rural farming communities in West Africa, was reported by Turner et al. 
(2005a). 
Other post-harvest methods have been described for removing of aflatoxins from foods. 
These include 1) physical methods such as thermal inactivation, irradiation, sorting etc., 
2) chemical means, including solvent extraction, 3) adsorption for example using 
minerals, e.g., phyllosilicate clays, 4) a variety of chemical degradations e.g., acids, 
alkalis, aldehydes, oxidising agents, ammoniation and sodium bisulphate, and 5) 
biological decontamination. Most of these available methods are appropriate only for 
feeds as they alter the nutritional and taste properties of the foods, making them 
unsuitable for human consumption (Wild and Hall 2000). 
 
2.5.2. Interventions at the individual level 
One means of intervening to reduce aflatoxin exposure would be by dietary changes 
aiming to avoidance of foods with high aflatoxin contamination such as maize and 
groundnuts, and increased consumption of crops like rice with a lower incidence of 
Aspergillus flavus infestation. However, this would mean alteration to the local 
agricultural practices and the local dietary habits of the population which in most cases 
would be a rather infeasible task (Sylla et al. 1999, Wild and Hall 2000). 
For high risk individuals e.g. people with chronic HBV infection, some other 
approaches could be considered. Drugs (oltipraz) (Kensler et al. 1998), dietary 
constituents like chlorophyllin (Egner et al. 2001), or probiotics (El-Nezami et al. 
2000b) could be used to modulate aflatoxin metabolism once ingested or to prevent 
their absorption from the gastrointestinal tract. 
Oltipraz is effective in blocking aflatoxin adduct formation and hepatocarcinogenesis in 
rodents by inducing the GST levels which lead to an increased inactivation of aflatoxins 
(Kensler et al. 1994). The ability of oltipraz to modulate aflatoxin metabolism in 
humans has been demonstrated in China by Kensler et al. (1998). However, sustained 
health therapy is expensive and is not likely to be feasible, given the health budgets of 
developing countries and their other pressing health problems (Williams et al. 2004). 
Chlorophyllin, a water-soluble form of chlorophyll, is used extensively as a food 
colorant, and is thought to form molecular complexes with carcinogens, including 
aflatoxins, thereby blocking their bioavailability. It may be therefore used to bind 
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aflatoxins and in that way to reduce the amount of the toxin reaching the liver. 
Chlorophyllin has been shown to be an effective anticarcinogen against aflatoxin-
induced hepatocarcinogenesis in experimental models (Dashwood et al. 1998) and it 
was also recently evaluated in a clinical trial in a population at a high risk of exposure to 
aflatoxin. Administration of chlorophyllin three times a day led to a 50% reduction in 
the median level of urinary excretion of AFB1-N7-guanine compared to placebo (Egner 
et al. 2001). 
Probiotic bacteria are defined as micro-organisms that have a beneficial effect on the 
health of the host. Some probiotic bacteria strains have the ability to bind a range of 
fungal toxins including aflatoxins, and this ability has been studied extensively in vitro 
(El-Nezami et al. 1998a,  1998b, Haskard et al. 2001, Peltonen et al. 2001, Gratz et al. 
2004) and in vivo (El-Nezami et al. 2000a, Gratz et al. 2005). The ability of these 
bacteria to reduce human aflatoxin exposure has also been tested in a small trial 
performed in Egypt (El-Nezami et al. 2000b). The low price of probiotic bacteria and 
their incorporation in traditional foods such as fermented milks, fermented vegetables or 
fermented cereals in many parts of the world makes this approach an appealing one. In 
the context of this work, the use of probiotic bacteria in reducing human aflatoxin 
exposure will be given additional attention. 
 
The use of probiotic bacteria as a method for reduction of human aflatoxin exposure 
In the dairy industry, the most widely used probiotic bacteria belong to the group of 
lactic acid bacteria. This is mainly due to their ability to produce lactic acid as the major 
end product of fermentation of carbohydrates. Lactic acid producing fermentation is 
certainly one of the oldest methods of food preservation and production known to 
mankind causing palatable flavor and texture changes, as well as exercising a 
preservative effect on the fermented product. It has been estimated that 25% of the 
European diet and 60% of the diet in many developing countries consists of fermented 
foods (Holzapfel et al. 1995). These include not only fermented milks but also 
fermented vegetables and cereals and other products around the world. 
Currently, the best studied probiotic bacteria are the lactic acid bacteria, particularly 
Lactobacillus and Bifidobacterium species (Rolfe 2000). The main beneficial effects 
attributed to lactic acid bacteria are prevention of diarrhoeal and gastrointestinal related 
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diseases, but antimutagenic and anticarcinogenic effects and beneficial effects on 
immune disorders have also been reported (Ouwehand et al. 2002). Additionally, meta-
analysis studies have demonstrated that probiotics indeed do have scientifically 
demonstratable effects on human health (Sazawal et al. 2006, Szajewska et al. 2006). 
Several studies have examined the ability of specific strains of lactic acid bacteria to 
remove aflatoxins from contaminated media. It was found that within a given species, 
not all strains were equivalent in terms of toxin binding. The capacity for AFB1 removal 
was a characteristic of only specific strains, with efficacy varying markedly from 
species to species (El-Nezami et al. 1998a, Peltonen et al. 2001). 
The most efficient strains in binding AFB1 were shown to be L. rhamnosus strain GG 
(LGG) and L. rhamnosus strain LC 705 (LC705), but L. gasseri, L. acidophilus, L. casei 
Shirota and Propionibacterium freudenreichii subsp. shermanii JS (PJS) had also 
shown some ability to remove AFB1 (El-Nezami et al. 1998a, Peltonen et al. 2001). 
Non-viable bacteria were more efficient at removing AFB1 than viable bacteria (El-
Nezami et al. 1998b), implying that metabolic degradation of the toxin is not the 
mechanism responsible for the removal of the toxin. It has been proposed that AFB1 is 
bound by the bacterial cell wall polysaccharides and peptidoglycanes (Haskard et al. 
2001). Bacterial concentrations must exceed 109 bacteria/ml to achieve effective 
removal of AFB1 (El-Nezami et al. 1998a). The total number of AFB1 molecules that 
can be bound to a single viable bacterium has been estimated to exceed 107. An 
important consideration is the demonstration that once bacteria bind aflatoxin they 
appear to lose their ability to bind to the intestinal mucosa thus preventing further 
prolonged contact between the absorptive surface and the toxin leading to removal of 
the toxin by the fecal route (Kankaanpää et al. 2000). 
A mixture of LC-705 and PJS is currently used by the food and feed industry as bio-
preservative and probiotic preparation (Bioprofit), making it a promising candidate for 
future applications. Bioprofit, is a patented combination of starter bacteria that 
efficiently prevents the growth of yeasts, moulds and some contaminant bacteria, and 
can be used for the preservation of different foods such as cheese and bread. It has been 
claimed that this mixture has the ability to inhibit Aspergillus growth (Valio Ltd). 
The in vitro ability of this probiotic mixture to bind AFB1 has also been demonstrated 
(Gratz et al. 2005), and in vivo tests have suggested that the mixture could reduce AFB1 
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bioavailability from ligated duodenal loops of one week old chickens by reducing toxin 
absorption (El-Nezami et al. 2000a, Gratz et al. 2005). To clarify the benefit of this 
probiotic mixture in individuals exposed to aflatoxin via their diet, a pilot clinical trial 
on aflatoxin-probiotic interaction was carried out in Egypt. Twenty Egyptian volunteers 
were recruited for an intervention using the probiotic mixture as a supplement (El-
Nezami et al. 2000b). Consumption of the probiotics significantly influenced the fecal 
content of AFB1. 
 
2.6. Rationale of the present study 
 
Aflatoxins are produced by Aspergillus moulds contaminating dietary staples in the 
developing countries. They are toxic, carcinogenic and mutagenic in humans, and recent 
evidence suggests that their effects extend to immunosuppression and impaired growth 
in children. AFB1 is the most prevalent and potent form of aflatoxins and is classified as 
a class 1A human carcinogen by the International Agency for Research on Cancer. 
Following ingestion of contaminated food, AFB1 is metabolized by specific enzymes of 
the cytochrome P-450 enzyme superfamily to produce various hydroxylated derivatives 
and a highly reactive epoxide, reacting with cellular proteins or DNA. Aflatoxin 
metabolites are excreted in urine and feces, as well as into the milk of nursing mothers 
if they have consumed aflatoxin contaminated food. A number of molecular dosimetry 
methods have been developed for assessing aflatoxin exposure by monitoring levels of 
aflatoxin metabolites in biological samples such as blood, urine and milk. 
Chronic carriage of hepatitis B (HBV) and C viruses (HCV) and chronic exposure to 
aflatoxins are considered to be the major risk factors in the development of 
hepatocellular carcinoma (HCC) in countries with a high incidence of the disease. In 
many of these areas, up to 20% of the population is chronically infected with hepatitis 
viruses, and the aflatoxin exposure is also reported to occur at high levels. Egypt is an 
African country where the annual prevalence of HCC has increased significantly during 
the past decade. Aflatoxins have been detected in a number of foods like corn, wheat, 
peanuts, corn oil, different spices and dairy products that are an essential part of the 
Egyptian diet. In all, 5.6% of the population are HBV chronic carriers, and the 
prevalence of HCV infection (20%) is the highest in the world. Reducing or eliminating 
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aflatoxin exposure in countries where both aflatoxin exposure and chronic hepatitis 
virus infections are prevalent could potentially reduce the risk of HCC development. 
Considering that the early life environment is crucial for growth and development in 
later life, long term pre- and postnatal exposure to aflatoxins could be one of the factors 
contributing to growth faltering and/or the early onset of HCC in countries with a high 
incidence of the disease. In West Africa, elevated biomarker levels in children have 
been repeatedly reported with those children displaying higher biomarker levels when 
they are infected with HBV. A number of studies suggest that susceptibility to aflatoxin 
is greatest in the young, and therefore aflatoxin exposure occurring via mother’s milk or 
weaning foods may be a major factor contributing to the development of HCC in later 
life. 
Therefore, a reduction of early life exposures and potentially of the risk of HCC 
development later in life is a goal worth achieving. One approach may be manipulation 
of aflatoxin absorption in lactating mothers by providing them with probiotic bacteria 
able to bind aflatoxins. The design of such a project demands an understanding of the 
aflatoxin exposure levels and patterns in the population of interest, for example, this 
kind of information for Egypt was lacking from the literature. 
Specific strains of probiotic bacteria, in addition to having by definition potential 
benefits for the health of the host, have been shown to possess the ability to bind 
aflatoxins and remove them from contaminated media (in vitro). The effectiveness of 
probiotics in binding aflatoxins has been investigated also in vivo, but the potential of 
reducing the biologically effective dose of aflatoxin exposure in human populations has 
never been assessed via an intervention in a region with known high aflatoxin exposure 
such as Southeast China. 
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3. AIMS OF THE STUDY 
 
The overall aim of this study was to evaluate the need for and feasibility of developing a 
method to reduce aflatoxin exposure in infants, young children, and young adults in the 
developing countries. For this purpose, the study investigated the patterns and levels of 
aflatoxin exposure in different study groups from Egypt, Guinea, or China, and 
characterized the potential of specific probiotics as a dietary intervention approach to 
reduce the risk of exposure to aflatoxins. 
Consequently, the specific research questions in this dissertation were: 
 
• How serious is the problem of aflatoxin exposure in a group of nursing Egyptian 
mothers and their children? Which factors possibly affect the AFM1 levels in 
maternal milk? These research questions were clarified by determining the levels 
of aflatoxin M1 (AFM1) in mother’s milk in Egypt and by identifying 
associations of AFM1 levels with several socioeconomic, demographic, dietary 
and environmental factors (Studies I and II). 
 
• How high or low is the exposure of the Egyptian children compared to children 
living in an area with known high aflatoxin exposure? This research question 
was addressed by determining the urinary levels of aflatoxin B1 (AFB1), B2 
(AFB2), G1 (AFG1), G2 (AFG2), M1 (AFM1), Q1 (AFQ1) in children from Egypt 
and Guinea (Study III) 
 
• Can probiotic supplementation reduce the biologically effective dose of AFB1? 
This research question was examined by determining the changes in urinary 
levels of aflatoxin B1 N7-Guanine (AFB1-N7-guanine) in male students from 
China following a dietary supplementation with specific probiotics (Study IV 
and V). 
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4. SUBJECTS AND METHODS 
 
4.1. Study subjects 
 
4.1.1. Egypt and Guinea Studies (Studies I, II and III) 
Study subjects and design 
The Egypt Study was conducted in Qalyubiyah governorate, Egypt. Qalyubiyah 
governorate is located in the eastern Nile region near the head of the Nile Delta. The 
area is bordered in the south by Cairo and Giza governorates. The governorate is 
famous for its agricultural production of maize, cotton, wheat, as well as fruits and 
vegetables. In the Qalyubiyah governorate approximately two thirds of the population 
live in rural areas, and the humid and hot environment promotes mould growth and 
aflatoxin production (El-Shewey 1992). 
The Egypt Study consisted of a cross-sectional part and a cohort follow up. In the cross-
sectional part (Study I) 388 Egyptian mothers from Qalyubiyah governorate provided 
breast milk samples for determination of AFM1 level and its associations with factors 
affecting AFM1 presence (dietary, socioeconomic, demographic, environmental 
factors). In the cohort follow up (Study II), 50 mothers from the above sample with 
significantly increased AFM1 levels were selected for longitudinal assessment of breast 
milk AFM1 levels at monthly intervals over a one year period. Since the cohort was 
selected on the basis of breast milk AFM1 level, it does not represent the general 
aflatoxin exposure of the population in the region, instead it deliberately illustrates a 
group exposed to aflatoxins. At the end of the follow up period, the children of these 50 
Egyptian mothers provided a single urine sample for aflatoxin biomarker analysis and 
comparisons with urine samples provided from 50 children of Guinea, a country with a 
verified high aflatoxin exposure (Study III). The Guinean children (25 boys and 25 
girls) were selected randomly out of a group of 100 HBV positive children who were 
taking part in a study in lower Kindia, Guinea, being conducted by the University of 
Leeds, UK in cooperation with the Institut Pasteur de Guinée (IPG), Kindia, Republic of 
Guinea. The children were selected from a defined area in lower Kindia, Guinea, 
because of the previous observations of high aflatoxin exposure levels (Diallo et al. 
 53 
1995, Sylla et al. 1999). The samples of the Guinean children were kindly provided by 
the Molecular Epidemiology Unit, University of Leeds, UK. 
The design of the Egyptian Study is presented in Figure 12. 
 
 
Figure 12: The design of the Egypt Study and samples collected for Studies I, II and III. 
 
Sample size estimations 
The Egypt Study was designed to provide the necessary background data for the design 
of an intervention study aimed at reducing maternal and infant aflatoxin exposure in the 
Egyptian population. A previous study in the same region (Qalyubiyah governorate) 
(El-Shewey 1992) reported that 11% of mothers screened for aflatoxins in their breast 
milk were found to be positive. We anticipated that a group of 50 mothers with monthly 
collections of breast milk samples for a year of follow up would provide a reasonably 
large number of samples (50 mothers x 12 months= 600 samples), even after possible 
drop outs (20%), for identification of factors affecting AFM1 presence in breast milk. 
Thus, to obtain a group of 50 mothers, it was originally planned to screen approximately 
500 mothers for aflatoxins in their breast milk. Nevertheless, while the study was being 
conducted, it transpired that the percentage of AFM1 positive mothers was considerably 
higher than expected, and therefore the final number of screened mothers was 388 of 
whom 138 (36%) were positive for breast milk AFM1. 
 
 
 
Study I: Screening of mothers 
 388 mothers, AFM1 in breast milk 
Recruitment: 50 mothers 
Study II: One-year follow up  
Breast milk collected monthly from 50 mothers 
May 03 Aug 03 Sept 03 Dec 03 Oct 04 Dec 04 
Study III:Urine samples 
50 children (Egypt vs. Guinea) 
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Data collection 
The mothers had given birth in the New El-Qalyub Hospital and were recruited and 
followed up by the nurses in the hospital. Dietary, socioeconomic, demographic and 
clinical data were obtained by an interview conducted by the health care nurse and the 
use of questionnaires. The dietary questionnaires were used to assess the intake of 
potential dietary sources of aflatoxins during the initial screening and also the follow up 
periods. During the screening period, the structured food frequency questionnaire (FFQ) 
was used to record the intake of the most common foods consumed over the one month 
period before collection of the breast milk samples from 388 mothers. The FFQ 
consisted of two components, a food list and a frequency response section. The data on 
food use were expressed as frequencies ranging from several times a day to never, while 
the amounts of foods used were fixed in serving sizes described by standard weight and 
volume measures of the servings commonly consumed by this population. During the 
one year follow up period, a structured questionnaire was used each month to record the 
usual food intake over the previous week before the breast milk sample collection from 
the cohort of 50 mothers. The questionnaire of the follow up period was less detailed 
than the FFQ covering the previous week’s consumption with responses designated as 
either yes or no. The questionnaires focused on foods more likely to contribute to the 
dietary intake of aflatoxins, i.e. grain products (wheat bread, corn bread, pasta, rice, 
corn), milk and milk products (hard cheese, feta cheese, cream), legumes (beans, 
lentils), meat (chicken, beef, lamb), fish, corn oil, cotton seed oil, dried fruits, and 
peanuts (Selim et al. 1996, El-Nezami et al. 2000b, El-Sayed et al. 2003). 
Other relevant information (age, working status, level of education, number of 
miscarriages, health status, medication) was also recorded during the initial screening. 
The socioeconomic status of the households was dichotomized in categories of either 
higher or lower (HSES/ LSES). HSES included families with one or both parents 
working and at least one occupation demanding higher education (teachers, nurses, 
government employees, police officers etc.), whereas for LSES one or neither of parents 
were working and the work did not demand higher education (butcher, carpenter, tailor, 
salesman, conductor, driver, farmer etc.), respectively. 
Maternal HBV status, child’s birth date and the anthropometrical data (mother’s weight 
and height, baby’s weight and height at the time of the initial screening and at delivery) 
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were taken from the reports of the New El-Qalyub Hospital where the mothers had been 
followed since the delivery. Children’s body weights were measured by the nursing 
staff using a Tanita 1584, Precision weighing balance, Bradford, MA (max weight 20 
kg, accuracy 50 g). 
 
Descriptive information 
In the first part of the Egyptian Study (Study I), the mothers were screened for AFM1 in 
their breast milk. From 409 contacted mothers, 388 (participation rate 95%) provided 
one breast milk sample during May-September 2003. The median age of the mothers 
was 25 years (range 15- 47), most mothers (71.6%) already had one or more children, 
and 14% had previously had a miscarriage (Table 5). Most households (76%) belonged 
to LSES category while 89% of the mothers were not employed and were either at home 
or involved in farming. Fifteen percent of the mothers were obese (BMI>30), and obese 
mothers were consumers of corn oil more frequently than the non obese mothers (84 vs. 
67%, p= 0.020). A few of mothers (6.2%) reported a health problem associated with 
liver or intestine function, while two percent of the mothers reported consumption of 
medicines such as blood pressure reducing tablets and anti-depressant tablets, or dietary 
supplements such as iron and calcium tablets. 
Beans, corn bread, corn oil, wheat bread and cotton seed oil were used by most of the 
mothers on a daily basis (Figure 13), but mothers belonging to the LSES category 
consumed beans (p= 0.009), corn oil (p= 0.001), and cotton seed oil (p= 0.001) more 
frequently than mothers belonging to the HSES category. 
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Table 5. Descriptive maternal data in the cross-sectional part of the Egyptian Study 
(Study I). 
  
% of mothers (n) § Median (IQR) Range 
Lactation stage* (months)  100 (384) 5 (2-8) 0.2-33.0 
Age (years)  100 (381) 25 (22-30) 15-47 
Number of miscarriages# Total 
0 
1-3 
100 (383) 
  86 (331) 
14 (52) 
- 
 
- 
Number of children## Total 
1 
2-7 
100 (384) 
  28 (109) 
  72 (275) 
- - 
BMI Total 
<20 
20-<25 
25-<30 
>30 
100 (336) 
    2     (8) 
  32 (106) 
  51 (171) 
15 (51) 
26.0 (24-28.5) 15.8-68.9 
Employment Total 
unemployed 
employed 
100 (382) 
  89 (339) 
  11   (43) 
- - 
Socioeconomic status Total 
LSES§§ 
HSES§ 
100 (384) 
  76 (293) 
  24   (91) 
- - 
§Mothers who provided the required information 
*The number of months that mother has been lactating 
#Prior to index child, ##Including index child, 
§§
 (LSES) Low socioeconomic status, (HSES) High socioeconomic status 
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Figure 13. Food use among lactating Egyptian mothers. Frequency distributions of 
responses to selected foods grouped according to either daily or weekly/ monthly 
consumption. 
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The children in the cross-sectional part of the Egyptian Study included 227 boys and 
159 girls (Table 6). The mean age of the children was 5.9 months. There were no 
reported illnesses within any of the infants. For assessing children’s growth status, the 
measured anthropometric values (baby’s weight and height) were expressed as standard 
deviations (z-scores) below or above the median value of the international reference 
population as recommended by the National Centre of Health Statistics/World Health 
Organization (WHO) (WHO 1995). Weight for height z-score (WHZ), weight for age z-
score (WAZ), and height for age z-score (HAZ) below -2 reflects malnutrition, while a 
value below -3 refers to severe malnutrition. Among the children, the prevalence rate 
for stunting (HAZ≤-2) was 35.7%, for being underweight (WAZ≤-2) 14.4%, and for 
wasting (WHZ≤-2) 0.6%. According to the WHO criteria (WHO 1995) these 
frequencies are high, moderate and infrequent, respectively. A total of 78 (23.4%) 
children had a z-score of ≤-3 in at least one parameter (extreme malnutrition). Median 
z-scores (IQR) for the infants were below zero for stunting and being underweight, but 
not for wasting. 
 
Table 6. Sex, age and growth status of the infants in the cross-sectional part of the 
Egyptian Study (Study I). 
 
 % of children (n) Median (IQR) Range 
Sex* boys 
girls 
  58 (227) 
  42 (159) 
-  
Age (months)   5 (2 to 8) 0.2 to 33.0 
Height for age z-score (HAZ)** total 
> -2 
-3 to -2 
≤ -3 
100 (322) 
  64 (207) 
  18   (56) 
  18   (59) 
-1.49 (-2.63 to 0.02) - 4.2 to 2.9 
Weight for age z-score (WAZ)** total 
> -2 
-3 to -2 
≤ -3 
100 (375) 
  86 (321) 
    9   (35) 
    5   (19) 
-0.45 (-1.47 to 0.43) - 4.5 to 4.6 
Weight for height z-score 
(WHZ)** 
total 
> -2 
-3 to -2 
≤ -3 
100 (351) 
  99 (349) 
    1     (2) 
     0     (0) 
0.82 (0.17 to 1.66) -2.3 to 4.8 
*Sex information were missing for two children 
**Z score less than -2 for HAZ (stunting), WAZ (being underweight) or WHZ (wasting) is 
defined as malnutrition, while smaller than -3 as severe malnutrition. Malnutrition status is 
based on World Health Organization Guidelines. 
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Fifty mothers who were positive for AFM1 in breast milk participated in the one year of 
follow up (Study II). Of these, 26 (52%) gave 12 monthly breast milk samples, while 20 
(40%), 3 (6%) and one (2%) mothers gave 5, 9, and 4 monthly samples, respectively, 
because they had terminated breastfeeding. A total of 443 breast milk samples were 
collected during the 12 month follow up period. Most mothers were not employed 
(92%) but belonged to small farming communities and were therefore undertaking some 
farm work and domestic chores (Table 7). The employed mothers (8%) were either in 
nursing or teaching. For 17 mothers (34%) this was their first child, while the rest had 2-
5 children. Seven mothers (14%) had previously had one miscarriage, and one mother 
(2%) had experienced three miscarriages. At the outset of the follow up period, the 
average infant age (same as lactation time) was 9.2 months old (range 3–20), while at 
the end of the follow up it was 17.2 (range 9–29). All mothers were healthy. 
 
Table 7. Descriptive maternal data of the follow upstage of the Egyptian Study (Study 
II). 
  % of mothers 
(n) 
Median (IQR) Range 
Lactation stage* (months) beginning of follow up 
end 
100 (50) 
100 (50) 
8.5  (6-11) 
17 (14-22) 
3-20 
9-29 
Age (years)  100 (50) 24.5 (21-28) 15-40 
Number of miscarriages# Total 
0 
1 
3 
100 (50) 
  84 (42) 
   14   (7) 
     2   (1) 
- 
 
- 
Number of children## Total 
1 
2-5 
100 (50) 
  34 (17) 
  66 (33) 
- - 
BMI Total 
<20 
20-<25 
25-<30 
>30 
100 (42) 
    2   (1) 
   43 (18) 
   41 (17) 
  14    (6) 
25.3 (24.0-28.0) 19.5-36.4 
Employment  Total 
unemployed  
employed 
100 (50) 
  92 (46) 
   8   (4) 
- - 
Socioeconomic status Total 
LSES§ 
HSES§ 
100 (49) 
  78 (38) 
  22 (11) 
- - 
*The number of months that a mother has been lactating 
#Prior to index child, ##Including index child 
§(LSES) Low socioeconomic status, (HSES) High socioeconomic status 
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At the end of the follow up period (October 2004), a single urine sample was collected 
from the children of the Egyptian Study (Study III). In all, 30 children were fully 
weaned (had stopped breast feeding) and 20 were partially weaned (Table 8). All 
Egyptian children were diagnosed to be HBV negative as determined by HBsAg in 
serum. The median age of the children was 1.5 years. The median age of the Guinean 
children was 3 years, and they all were fully weaned. All Guinean children had been 
exposed to aflatoxins as determined by the aflatoxin albumin adduct concentrations in 
their serum. 
 
Table 8. Descriptive data on the Egyptian and the Guinean children at the time of urine 
sample collection (Study III) 
 Egyptian children* Guinean children* 
 % of children (n) Median (IQR)  
Range 
% of children (n) Median (IQR) 
 Range 
Sex       boys 
            girls 
68   (34) 
32   (16) 
 50 (25) 
50 (25) 
 
Age (years)**  1.5 (1.3-1.75) 
1.08-2.5 
 3 (2-3)  
2-10 
HBV   negative  
            positive 
100 (50)   
100 (50) 
 
Weaning status 
      partly-weaned 
 
40 (20) 
  
- 
 
      fully-weaned 60(30)  100 (50)  
*The collection of the urine samples of the Egyptian children took place during October, and of 
the Guinean children during July/August 
**The age of the Egyptian children was calculated based on the date of birth, while the 
age of the Guinean children was that reported by the parents 
 
 
4.1.2. China Study (Study IV and V) 
 
Study subjects and design 
The study population was selected from an area of Guangzhou in Guangdong province 
which is located in the southern China. In this area the exposure to aflatoxin via foods and 
diet is known to be common. 
The study was conducted in two parts. First, 300 male students at the Sun Yat- Sen 
University were screened for AFM1 from a spot urine sample (Study IV). Of those with 
a detectable level of AFM1 (>0.08 ng/ml) (142/300, 47%), 90 were selected for the 
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second part of the study (Study V) which was a randomized, double-blind, placebo-
controlled trial with two parallel groups (Figure 14). Exclusion of individuals was based 
on abnormal hematological values and outlying AFM1 (< 0.008 or > 20 ng/ml). The 
subjects were randomly assigned to two groups (n=45/group), one receiving the 
probiotic preparation and the other receiving the placebo preparation. The subjects 
received written and oral directions to take two capsules per day immediately prior to 
their main meals (breakfast and dinner). The probiotic preparation contained a mixture 
of the strains Lactobacillus rhamnosus LC705 and Propionibacterium freudenreichii 
ssp shermanii (1:1 wt/wt) at a dose level of 2-5 x 1010 CFU/day. The placebo capsules 
contained only cellulose. The probiotic strains used are of GRAS grade (generally 
recognized as safe) and are commonly used in the manufacturing of many dairy 
products. The compliance to the study protocol was assessed based on the presence of 
Lactobacillus rhamnosus LC705 in fecal samples taken at the same time points as the 
urine samples. The subjects provided an early morning single urine sample on the 3rd 
and 5th week of the intervention period, and after a 5-week post intervention period. 
 
 
Figure 14: Design of the China Study (Studies IV and V). A total of 300 male students 
were screened for AFM1 in a spot urine sample. Of those with a detectable level of 
AFM1 (>0.08 ng/ml), 90 were selected for a 5-week intervention study. The subjects 
were randomly assigned to two groups, one receiving the probiotic preparation and the 
other receiving placebo preparation. The subjects provided an early morning single 
urine sample in the 3rd and 5th week of the intervention period, and after a 5-week post 
intervention period. 
 
Study IV: Baseline 
n= 90 
5-week intervention period 
weeks 
Probiotic n=45 
Placebo n=45 
5-week post intervention period 
 
1 2 3* 4 5* 1 2 3 4 5* 
Study IV: Screening 
        n=300 
*Urine sample collection 
Study V: Intervention 
n=90 
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Sample size calculation 
The calculation of the sample size of 90 subjects with 45 subjects in each arm was based 
on the assumption that intervention with probiotic bacteria could reduce the level of AFB1-
N7-guanine by at least 25% when compared with the placebo, giving a standardized effect 
of ∆ = 0.5. Using these assumptions the required sample size for two-sided significance of 
5% and power of 80% was 86 subjects per arm. Using 0.5 as the correlation between 
repeated AFB1-N7-guanine measurements (baseline + 2 intervention measurements + post 
intervention), the required number of subjects was reduced to 33 per arm. The two phases 
of the study (intervention and post intervention) are considered as separate phases. To 
compensate for the anticipated drop-out (20%), a total of 90 subjects was randomized, 45 
in each arm. 
 
Data collection and descriptive information 
Students that failed to provide all of the required samples during the intervention and 
post intervention periods were excluded from the study. Overall 90% of the subjects 
(n=81) delivered the required urine samples (39 in the probiotic group and 42 in the 
placebo) (Figure 15). 
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Figure 15. Flow diagram of the progress through the phases of the probiotic randomised 
trial (Study V) 
 
 
The 90 selected Chinese students underwent a complete health examination: medical 
history, smoking status, physical examination, routine hematological and clinical 
biochemistry tests on hepatic and renal function, and antigens to hepatitis B virus 
(HBsAg) (14 subjects were tested as being positive for HBsAg) (Table 9). All students 
were clinically healthy according to all clinical chemistry values which were within the 
reference range for normal values and no other differences were noted in liver function 
parameters. Eleven HBsAg positive subjects (6 in the probiotic and 8 in the placebo 
group) were included in the study. The clinical chemistry measurements and HBsAg 
determination were carried out at the Sun Yat-Sen University according to standard 
protocols. Antibiotics and/or traditional Chinese medicines and herbs had been used 
Assessed for eligibility (n=300) 
Excluded (n=210) 
• Abnormal blood /urine 
chemistry  (n=36) 
• No aflatoxin detected at 
screening (n=158) 
• Refused to participate 
(n=16) 
Randomised (n=90) 
45 probiotic 45 placebo 
Urine samples 
analyzed (n=156) 
Excluded (n=6) 
• 1 dropped out 
• 3 failed to provide sample 
during intervention 
• 2 failed to provide sample 
post intervention 
Excluded (n=3) 
• 3 failed to provide sample 
during intervention 
Urine samples 
analyzed (n=168) 
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during the preceding two months by 21 students (25%), evenly distributed between the two 
study groups. 
 
 Table 9: Descriptive data on the male students participating 
in the China study (Study IV). 
 Range 
Age (years) 18 - 24 
Body weight (kg) 45 - 85 
Body height (cm) 158-182 
HBV status    positive, n (%) 14 (17) 
Herbal chinese medicine 
users, n (%) 
21 (25) 
 83 subjects provided all urine samples during the intervention 
 
Consumption of foods known to be the most common sources of dietary aflatoxins in 
China was assessed using a structured FFQ filled at the same time as the interview at the 
baseline period. All subjects resided in student accommodation and consumed their 
main meals (breakfast, lunch and dinner) at the student restaurant operated by the 
university. During the 5-week intervention period, the subjects consumed their normal 
diets. With respect to the consumption of possible sources of dietary aflatoxins, the 
subjects represented a homogenous population of students eating their main meals at the 
same cafeteria. There were no significant differences between the two intervention 
groups in the intakes of foods known to be the most common sources of dietary 
aflatoxins in China (Table 10). 
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Table 10. Weekly intake of major foods in the diet of healthy Chinese male students 
receiving either a probiotic or placebo preparation. (Study IV) 
                                                                                Weekly intake (mean ± SD) 
Foods (servings) Probiotic group (n = 39) Placebo group (n = 42) 
Rice (scoops) 157 ± 36 164 ± 35 
Bread (slices) 9.9 + 5.1 10.0 + 4.6 
Pork (chops) 6.5 ± 4.7 6.9 ± 3.8 
Chicken(chops) 6.4 ± 4.4 4.7 ± 4.1 
Beef (chops) 2.8 + 4.3 2.8 + 4.0 
Fish (chops) 2.1 + 3.3 2.2 + 3.6 
Beans (scoops) 5.5 + 2.8 5.1 + 2.9 
Noodles (scoops) 1.3 + 1.8 1.5 + 2.1 
Peanuts, total (handfuls) 0.4 ± 1.0 0.3 ± 0.6 
No differences were observed between the probiotic and placebo arms in the intakes of foods 
known to be the most common sources of dietary aflatoxins in China (p>0.05, Mann-Whitney). 
 
 
4.2. Methods 
 
4.2.1. Aflatoxin standards 
The AFB1-N7-guanine standard was synthesized in the laboratories of the Department of 
Clinical Nutrition, University of Kuopio since it was not available commercially. The 
experimental procedure for synthesis of the AFB1-N7-guanine standard is described in 
detail below. The other aflatoxin standards, AFB1, AFB2, AFG1, AFG2, AFM1, AFQ1 
were purchased from Sigma/Aldrich Chemical Co (St Louis, MO, USA), dissolved in 
methanol and stored at -20 oC wrapped in aluminium foil before use. Aflatoxins are 
human carcinogens and care was exercised to avoid personal exposure. Appropriate 
decontamination procedures with 10 % sodium hypochlorite were used. 
 
In vitro synthesis of AFB1-N7-guanine adduct 
For the synthesis of the AFB1-N7-guanine, AFB1 was microsomally activated into the 
epoxide form and adducted to double stranded oligodeoxynucleotide. Subsequent acid 
hydrolysis of the formed AFB1 oligodeoxynucleotide adduct, yielded AFB1-N7-guanine. 
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AFB1-N7-guanine which was purified, identified and quantified by HPLC, LC-MS/MS 
and spectrophotometric techniques. 
For the activation of AFB1 and its adduction to the oligodeoxynucleotide, AFB1 was 
incubated with pyrazole induced mice liver microsomes (prepared by the Department of 
Pharmacology and Toxicology, University of Kuopio) and annealed oligonucleotides 
5´-TCA ATC TGC ATC ACT CAA C-3´and 5´-GAT GCA G-3´ (Johnston and Stone 
2000) (synthesized by the A.I.Virtanen Institute for Molecular Sciences, University of 
Kuopio, Kuopio, Finland) in aqueous phosphate buffer and magnesium chloride 
solution containing NADPH (Sigma/Aldrich, St Louis, MO, USA). NADPH was 
replaced with an equal volume of phosphate buffer (pH 6.8) in the mixtures used as the 
control. Reactions with AFB1 were performed under subdued light conditions to 
minimize potential photodecomposition of the resulting oligo adduct (Gopalakrishnan et 
al. 1989). The reaction mixture was incubated overnight at room temperature (25oC), 
and thereafter was stopped by boiling (5 min). The microsomal pellet was discarded 
after centrifugation (16000 g, 20 min, 4 oC). The AFB1 adducted oligos were 
precipitated from the supernatant by addition of cold ethanol. The supernatant was 
removed after centrifugation (16000 g, 20 min, 0-4oC) and the precipitated adducted 
oligonucleotides were washed with 80% cold ethanol. The adducted oligonucleotides 
were then hydrolysed with formic acid for 1 hr at room temperature. This resulted in 
sufficient depurination of the nucleic acids, and the release of AFB1-N7-guanine 
(Essigmann et al. 1977). Prior to HPLC analysis, potassium acetate was added for pH 
adjustment to 4.0, which is the optimal condition for the HPLC system. 
 
HPLC purification and spectrophotometric quantitation 
Reverse phase HPLC (model LC-10ADvp solvent delivery system and model SIL-
10Advp auto injector, Shimadzu, Japan) was used to separate the oligo-AFB1 
hydrolysates on an ODS-5 Brownlee column (220 by 4.6 mm, particle size 5 µm) fitted 
with a C18 guard column (Perkin Elmer, Norwalk, Conn.). The assay was carried out 
using an isocratic system of 70 % 20 mM ammonium acetate (pH 3.9) and 30 % 
methanol/acetonitrile (1:1) (Iyer and Harris 1993) with a flow rate of 1.5 ml/min, oven 
temperature 40 oC and injection volume of 20 µl. This method was determined to 
separate efficiently acid hydrolyzed products of the adducted oligo detected at 360 nm 
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(UV-10 Shimadzu detector). Repetitive collections of the predominant eluting 
compound accumulated sufficient amounts for LC-MS/MS identification. LC-MS/MS 
confirmed the identity of the compound to be AFB1-N7-guanine. The LC-MS/MS 
conditions are described in detail in the paragraph below. Afterwards, the adduct was 
purified again in HPLC with a different mobile phase [95% ethanol: water: acetic acid) 
(5:15:0.001, v/v/v), flow rate 1 ml/min]. The adduct (in 25% ethanol) was quantitated 
spectrophotometrically at 360nm (ε360= 18000 M-1cm-1) (Lin et al. 1977). The 
concentration of the adduct was calculated using the equation: C= (A x 1000 x 
Mr)/(18000 x b) where C is the concentration of the adduct (µg/ml), A the mean of 
three repetitive absorbance values, Mr the relative molecular mass of AFB1-N7-Gua (Mr 
= 479), and b the cell path length (1 cm). UV spectra in the range of 200-400 nm were 
measured by a Hitachi U-2000 spectrophotometer. The adduct was stored at -20oC 
under acidified conditions. Figure 16 displays the HPLC chromatogram of the AFB1-N7-
guanine final standard. The experimental procedures are summarized in figure 17. All 
chromatographic solvents were of HPLC grade quality and all reagents were of 
analytical grade or higher. 
 
 
Figure 16. HPLC chromatogram of AFB1-N7-guanine final standard (1,450 µg/ml) in 
25% ethanol, eluting at 4 min. retention time from the HPLC system. [mobile phase: 
70% 20 mM ammonium acetate, pH 3.9 and 30% methanol/acetonitrile (1/1); flow rate: 
1,5 ml/min; column: ODS-5 C18 220 x 4.6 mm]. 
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Figure 17. Schematic presentation of the experimental procedures for the synthesis of 
the AFB1-N7-guanine adduct standard 
 
 
Identification of AFB1-N7-guanine by LC-MS/MS 
The AFB1-N7-guanine adduct eluents collected by HPLC, were concentrated to a smaller 
volume (1 ml) under a gentle steam of nitrogen at room temperature and were analysed 
using an Ultimate/Famos LC system (LC Packings, Amsterdam, NL) with a gradient 
from 0% to 80% B over A in 8 min (A: 5 mM ammonium acetate in H2O, 0.1% acetic 
acid, B: 5 mM ammonium acetate in ethanol, 0.1% acetic acid) (Figure 18). The flow 
rate was 180 µl/ min. The samples were injected into a Genesis C18 column (50 x 2.1 
mm, particle size 4 µm) (Jones Chromatography, Hengoed, UK), with an injection 
volume of 30 µl. The LC mass spectra were recorded using a LCQ quadrupole ion trap 
mass spectrometer (Thermoquest, San Jose, CA). Full scan mass spectrum was 
measured for range m/z 300-600 and a second scan was used to measure the collision 
induced MS/MS spectrum of the AFB1 adducts. The spray needle was set to 4.00 kV in 
the positive ion mode. The inlet capillary temperature was maintained at 220 oC. 
 
 
 68 
 
Figure 18. Liquid chromatography ion trap mass spectrometry of AFB1-N7-guanine. (a) 
elution of m/z 480 molecular ions including the adduct at 6.5 min. (b) Selected reaction 
chromatogram of the adduct by monitoring m/z 329 and 152 fragments obtained by 
MS/MS of m/z 480. (c) the MS/MS spectrum resulting from colliding the major peak 
found in panel a. [mobile phase: gradient 0% to 80 % B in 8 min (A: 5 mM ammonium 
acetate in water, 0.1 % acetic acid, B: 5 mM ammonium acetate in ethanol, 0.1 % acetic 
acid); flow rate: 150 µl/min; column: Genesis C18 50 x 2.1 mm] 
 
 
4.2.2. Biomarker measurements 
 
Breast milk samples 
Aflatoxin extraction 
Breast milk was collected into a sterile plastic container by self-expression before 
nursing the baby. The sample was kept at 4 oC and frozen within one day at -20 oC prior 
to sample processing. Extraction of aflatoxins from milk samples was achieved by the 
modified the method of El-Nezami et al (1995). Briefly, 10 ml breast milk samples were 
warmed to 37oC and were shaken to distribute fat. For defatting, the samples were 
centrifuged (3000 g, 15 min, 5oC) and filtered through glass wool. To facilitate the 
passage through a C18 cartridge (Strata C18-E, 50 um, 70A, Phenomenex, USA), the 
samples were diluted 1:1 with milli-Q water. The cartridge was pre-activated with 10 ml 
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acetonitrile and then 10 ml of water, prior to passage of diluted breast milk at a flow rate 
of 3.5 ml/min. The loaded cartridge was then washed with 10 ml water, 10 ml basic 
acetonitrile/ water (1% ammonia, 10% acetonitrile) and 10 ml acidic acetonitrile/water 
(1% acetic acid, 10% acetonitrile). AFM1 was eluted with 5 ml acidic acetonitrile (1% 
acetic acid, 40% acetonitrile). AFM1 was extracted twice from the eluent with 2 ml 
dichloromethane. Following centrifugation (3000g, 15 min) to separate the layers, the 
two dichloromethane fractions were pooled and dried under nitrogen gas. The residue 
was dissolved in 0.7 ml of methanol. 
 
HPLC analysis 
Reverse phase HPLC (model LC-10ADvp solvent delivery system; model SIL-10Advp 
auto injector, Shimadzu, Japan) was used to determine the level of AFM1 in breast milk 
extracts. The columns used were ODS-5 C18 Brownlee reverse phase column (220 x 
4.6 mm, particle size 5 µm) with a C18 guard column (Perkin Elmer, Norwalk, Conn.). 
An isocratic system with water: methanol: acetonitrile 66:17:17, flow rate 1 ml/min, 
oven temperature 40 oC and injection volume of 30 µl were used. HPLC grade 
methanol, acetonitrile and dichloromethane were purchased from Sigma/Aldrich 
Chemical Co. (Kemia Oy, Helsinki, Finland). 
Detection was by excitation at 360 nm and emission at 440 nm (Fluorescence-10A XL, 
Shimadzu detector) (Figure 19). The concentrations of AFM1 in milk were estimated 
from a standard curve 0.04-10 ng/ml, prepared from AFM1 in chloroform (9.93 ug/ml) 
reference material RM 423 (LGC Promochem AB, Borås, Sweden). An AFM1 standard 
was injected every 10 injections as the quality control. The limit of detection of this 
method was 0.06 ng AFM1/ml methanol or 4.2 pg AFM1/ml of breast milk based on a 
10-ml breast milk sample, and reconstitution of extracts with 0.7 ml of methanol. 
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(a) 
 
(b) 
 
(c) 
 
 
Figure 19. HPLC chromatograms of AFM1. (a) AFM1 extracted from an Egyptian breast 
milk sample (1004 pg/ml breast milk or 14 ng/ml in methanol after extraction); (b) 
AFM1 standard 10 ng/ml in methanol; (c) AFM1 extracted from spiked water (250 
pg/ml water or 5 ng/ml methanol). [Mobile phase; water: methanol: acetonitrile, 
66:17:17; flow rate: 1ml/min; column: ODS-5 C18 220 x 4.6, fluorescence detection 
(ex. 360 nm, em. 440 nm)]. 
 
 
Method validation and confirmation of the breast milk AFM1 identity 
Validation and repeatability of the measurement of breast milk aflatoxin was carried out 
using breast milk samples kindly provided by the Breast Milk Centre of Kuopio 
University Hospital (Kuopio, Finland). AFM1 was not detected in these samples. In the 
recovery studies, seven breast milk samples (triplicates) were spiked with 12.5, 25, 50, 
125, 250, 375, 500 pg AFM1/ml milk. One water sample (triplicates) was spiked with 
250 pg AFM1/ml water. AFM1 was extracted from the samples as previously described. 
The average percentages of aflatoxin recovered were 88 ±28 and 94 ±8 from breast milk 
AFM1 
AFM1 
AFM1 
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and milli-Q water respectively. The correlation coefficient between AFM1 added and 
AFM1 recovered from spiked breast milk was 0.993. 
To assess the repeatability of the method, breast milk samples were spiked with 250 pg 
AFM1/ml milk and the measurement was replicated four times. The analysis gave a 
mean value of 205 ±15 pg/ml milk and 8% coefficient of variation. 
The identity of AFM1 was confirmed through spiking of positive breast milk samples 
with AFM1, and by derivatization of AFM1 to form AFM2a according to the method of 
the AOAC International (AOAC 1995) (Figure 20). Briefly, the breast milk extract 
containing AFM1 was evaporated to dryness and redissolved in 200 ul of hexane and 
200 ul of trifluoroacetic acid. After 10 min incubation at 40oC, the solvents were again 
dried under nitrogen gas, reconstituted in methanol and analyzed in an HPLC using the 
described method. 
 
(a) 
 
(b) 
 
Figure 20. HPLC chromatograms of AFM1 before (     ) and after derivatization (    ) to 
AFM2a. (a) AFM1 standard 10 ng/ml methanol, (b) AFM1 extracted from an Egyptian 
breast milk sample (50 pg/ml breast milk or 0.7 ng/ml methanol). [Mobile phase water: 
methanol: acetonitritle, 66:17:17; flow rate 1 ml/min, column PDS-5 C18 220x 4.6, 
fluorescence detection (ex. 360nm, em. 440nm)]. 
 
Urine samples  
The main focus in the analysis of the urine samples from the China Study (Studies IV 
and V) was on AFB1-N7-guanine, while in the urine samples from children (Study III) 
the primary aflatoxins and the hydroxylated AFB1 metabolites were determined. 
AFM2a 
AFM1 
AFM2a 
AFM1 
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Therefore, two different extraction methods were used for the analysis of the urine 
samples, one requiring the use of C18 cartridges, and another a combination of C18 and 
immunoaffinity columns for more thorough sample cleanup. The analysis of the 
Chinese student urine samples was performed in the University of Kuopio, and those of 
the children in the University of Leeds. 
 
Aflatoxin extraction 
To measure the AFB1-N7-guanine adduct in the samples from the Chinese students, 
after collection of the urine samples in Sun-Yat Sen University, China, an aliquot (25 
ml) was acidified with 1 N hydrochloric acid or 1 M ammonium formate, centrifuged, 
and passed through Bond Elut C18 cartridge (6 ml, 500 mg silica sorbent) (Varian, 
Middelburg, the Netherlands). The cartridge was washed with milli-Q water and 5% 
methanol. The ends of the cartridge were sealed with parafilm and the cartridges were 
shipped to the University of Kuopio for the analysis of the urinary levels of AFB1-N7-
guanine. In the University of Kuopio, the cartridges were washed with milli-Q water 
followed by 10% basic acetonitrile (ammonia: acetonitrile: water 1:10:90) and 10% 
acidic acetonitrile (acetic acid:acetonitrile:water 1:10:90). AFB1-N7-guanine was eluted 
from the cartridge using 40% acidic acetonitrile (acetic acid:acetonitrile:water 1:40:60), 
the eluent was extracted twice with two volumes of dichloromethane, and the extracts 
were pooled and dried in a vacuum. The vacuum-dried extracts were reconstituted in 
30% acetonitrile/methanol (1:1, v/v) in 20 mM ammonium acetate buffer (pH 3.9) for 
HPLC analysis. 
To measure the urinary aflatoxins in the samples from the children, after collection of 
the urine samples in the New El-Qalyub Hospital, Egypt, 20 ml of urine were treated as 
described above prior to shipment. The ends of the cartridge were sealed with parafilm 
and the cartridges were shipped to the University of Leeds (Leeds, UK). In the case of 
the samples from Guinea, the urine samples were shipped as such and the entire 
extraction procedure was performed in the University of Leeds. In the University of 
Leeds, the cartridges were washed with 5% methanol, and the aflatoxin residues were 
eluted with 3 ml of 1:1 methanol: 1% acetic acid followed by 5 ml methanol. The urine 
samples were extracted in batches of eight, and between each batch, the pump tubes 
were washed with methanol to avoid cross-contamination. The eluent was dried in a 
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vacuum to approximately 200 µl and was reconstituted in 2 ml of water for passing 
through AflaTest P immunoaffinity columns (IAC) (Vicam, Hallmark Analytical 
Ventures Limited, Chester, UK) under gravity. The IAC columns were attached to 
syringes to facilitate the procedure. The IAC were washed with 10 ml PBS followed by 
10 ml of water, were loaded with the 2 ml samples, and then were washed with 5 ml 
PBS followed by 10 ml of water. The aflatoxin residues were eluted with 5 ml of 95% 
methanol and were dried overnight in vacuum. The vacuum-dried extracts were 
reconstituted in 100 µl of methanol for HPLC analysis. 
 
HPLC analysis 
The analysis of the urine samples from the children (University of Leeds) was 
performed as follows: Reverse phase HPLC (Prostar 240 quaternary gradient solvent 
delivery module and Prostar 410 autosampler model, Varian, Inc.) was used to separate 
the primary aflatoxins and aflatoxin metabolites on an C18 Microsorb-MV column (150 
by 4.6 mm, particle size 5 µm) fitted with a C18 metaguard column (Microsorb 
A104MG, Varian, Inc.). Chromatographic separation was obtained by an isocratic 
system with a mobile phase of 30% acetonitrile/ methanol (1:1, v/v) in 20mM 
ammonium acetate buffer (pH 3.9) at a flow rate of 1.2 ml/ min. The assay oven 
temperature was 40 oC and the sample injection volume 10 µl. 
The concentrations of urinary aflatoxins were estimated from the respective standard 
curves: 8- 125 ng AFB1, 0.15- 2.5 ng B2, 15- 250 ng G1, 0.3- 5 ng G2, 1.5- 25 ng M1, 
25- 400 ng Q1/ml in methanol (regression coefficient >0.995 for all curves) 
corresponding to 40- 625, 0.75-12.5, 75- 1250, 1.55- 25, 7.5- 250, 125- 2000 pg/ml 
urine, respectively. The HPLC run (isocratic system: 30% acetonitrile:methanol 1:1, 
v/v, in 20 mM ammonium acetate buffer, pH 3.9, flow rate of 1.2 ml/ min) was repeated 
twice, and the results presented are mean values of the two runs. A mixture of all 
aflatoxin standards was injected after every 6 injections to assure the correct 
identification of the urine sample peaks based on their retention times. 
The limits of detection were 25, 0.35, 50, 0.8, 5, 100 pg/ml of urine for AFB1, AFB2, 
AFG1, AFG2, AFM1, AFQ1, respectively. The variation in the levels of the detection 
limit was due to the different fluorescent properties of the aflatoxins. 
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AFQ1 standard (Sigma/ Aldrich, Helsinki, Finland) appeared always as a double peak 
(Figure 21) possibly being a mixture of two AFQ1 epimers (Buchi et al. 1975). 
 
 
 
Figure 21: Mixture of AFB1, AFB2, AFG1, AFG2, AFM1, and AFQ1 standards in 
concentrations of 125, 2.5, 250, 5, 25, and 400 pg/ml urine, respectively. The AFQ1 
standard appeared always as a double peak. 
 
 
The analysis of the urine samples from the young male students (University of Kuopio) 
was performed as follows: Reverse-phase HPLC, a Shimadzu model SPD-10 Avp UV-
Vis detector (360 nm) in series with a Shimadzu RF-10AXL fluorescence detector 
(excitation 366 nm, emission 440 nm) was used to quantify aflatoxins. The HPLC 
column used was the ODS Spheri-5 Brownlee column (220 x 4.6 mm, 5 µm; Perkin 
Elmer) fitted with a C18 guard column (Perkin Elmer). Chromatographic separation was 
achived within 40 min with an isocratic mobile phase of 30% acetonitrile:methanol (1:1, 
v/v) in 20 mM ammonium acetate buffer (pH 3.9) at a flow rate of 1.5 ml/min. The 
assay temperature was 40°C, and the sample volume injected 10 µl. Samples were run 
in batches with authentic standards running between every 10 samples to control any 
changes to the retention time. The limit of detection for AFB1-N7-guanine was 5 pg/ml 
of urine. 
 
Method validation and confirmation of urinary aflatoxin identities 
The method validation was carried out using blank urine samples spiked with a mixture 
of known amounts of aflatoxin standards. In the University of Leeds, blank urine 
samples (n=8) were spiked with 625 pg AFB1, 12.5 pg AFB2, 1250 pg AFG1, 25 pg 
AFG2 and 125 pg AFM1/ml urine. The spiked urine samples were extracted with each 
AFB1 
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AFQ1 
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batch of samples. The method gave average recovery rates of 33±14, 46±16, 17±11, 
23±12, 42±22% for AFB1, AFB2, AFG1, AFG2 and AFM1 respectively. 
In the University of Kuopio, the method was evaluated based on the recovery of AFM1 
from spiked urine samples (n=3) and this was found to be 88±5%. The recovery of 
AFB1-N7-guanine was not determined due to the limited availability of the standard. 
Confirmation of aflatoxin identities in urine samples from the children was performed in 
10 (24%) out of the 42 positive Guinean samples and in 7 (30%) out of the 23 positive 
Egyptian samples by spiking with aflatoxin standards and co-chromatography using two 
different HPLC methods; an isocratic (mentioned above) and a linear 15% - 40% 
gradient system of B over A in 25 minutes (A: water/ acetonitrile/ phosphoric acid 100/ 
8/ 0.01 v/v/v and B: methanol/ acetonitrile/ phosphoric acid 100/ 8/ 0.01 v/v/v) at a flow 
rate of 1.2 ml/ min, oven temperature 37 oC and injection volume 10 µl. 
The identities of urinary AFB1 AFB2, AFG1, AFG2 and AFM1 were confirmed 
successfully by co-chromatography using both HPLC methods, while AFQ1 
identification gave controversial results (Figure 22). The peak thought to be AFQ1 in the 
urine samples co-eluted with the first peak of the AFQ1 standard when analyzed by the 
isocratic HPLC system, while it co-eluted with the second AFQ1 peak when analyzed 
with the gradient system. This was assessed by calculating the ratios of the two areas of 
the AFQ1 peaks for each spiked urine sample. The presumed urinary AFQ1 was detected 
in 15/50 Egyptian children (mean 159 pg/ml urine, range 75- 296) and 14/50 Guinean 
children (mean 946 pg/ml urine, range 167- 6352). However, the presence and levels of 
urinary AFQ1 are not discussed further in the following sections, since its identity was 
never successfully confirmed. 
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(a) 
 
(b) 
 
(c)  
 
 
Figure 22. Aflatoxins extracted from urine samples before (     ) and after spiking (    ) 
with a mixture of aflatoxin standards. (a) 290 pg AFQ1/ml urine, 12 pg AFM1/ml urine, 
2 pg AFB2/ml urine detected in urine sample (isocratic HPLC conditions) (b): 378 pg 
AFQ1/ml urine, 49 pg AFM1/ml urine, 3 pg AFG2/ml urine, 1.7 AFB2/ml urine, 436 
AFB1/ml urine detected in urine sample (isocratic HPLC conditions). (c): The spiked 
urine sample displayed in (a) analyzed with the gradient HPLC conditions. 
 
Confirmation of the AFB1-N7-guanine peaks in urine samples from the young Chinese 
males was performed using a gradient from 22% to 34% of methanol: acetonitrile (1:2, 
v/v) over 55 min and flow rate 0.2 ml/min. The aqueous buffer used was 0.1% formic 
acid: water. 
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4.3. Statistical treatment of the data 
 
4.3.1. Egypt and Guinea Studies (I, II and III) 
Screening phase (Study I) 
SPSS 11.0 for windows was used in the statistical analysis of the data. AFM1 values did 
not follow a normal distribution even after logarithmic transformation (p=0.005, 
Kolmogorov-Smirnov normality test). Therefore, to identify possible associations 
between AFM1 levels and related factors, the nonparametric Mann-Whitney U (or 
Kruskal-Wallis) test or Spearman correlation were used for the continuous variables. 
The mothers were dichotomized depending on the presence/absence of AFM1 in their 
breast milk, and the chi-square test was used to associate the presence of AFM1 in breast 
milk with categorical variables. Logistic regression models were used to analyse the 
association of each potential factor and AFM1 presence/absence. For the analysis of the 
FFQ data, the food consumption data were either regrouped into the two categories of 
“daily consumption” and “weekly or monthly consumption” (the category “never” was 
included into the “weekly or monthly consumption” category) or treated as a continuous 
variable, i.e. the reported frequencies of consumption were expressed as a number 
representing the frequency of consumption. eg. 1/ month, 1/ fortnight, 1/ week or 3-4 
times/ week calculated as 1/30 or 0.03, 1/14 or 0.06, 1/7 or 0.21, 3.5/7 or 0.5, 
respectively (Willet 1990). 
 
Follow up data on mothers (Study II) 
An exploratory approach was taken in the statistical analysis of the data. The outcome 
measure was taken to be the presence or absence of a detectable level of AFM1 in the 
breast milk sample. A logistic regression was performed to explore factors that were 
associated with the presence of AFM1. To account for clustering of samples within 
mothers, a multi-level logistic regression model was fitted using MLwiN version 2.02 
(Multilevel Models Project, Institute of Education, University of London) statistical 
software, with the Markov Chain Monte Carlo (MCMC) option for model fitting. This 
permits variation between mothers as well as variation between milk samples using a 
two-level model. All explanatory variables (mother’s age, working status, and number 
of children, month of the year on which the sample was collected and number of months 
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of lactation, consumption of corn oil, cotton seed oil and peanuts) were first included in 
the model and then variables removed stepwise if not significant. Care was taken to 
investigate various combinations of variables in the model and the model best 
describing the data was retained. A chi-square test was used to explore associations 
between the presence of AFM1 and the presence of AFB1, AFB2, AFG1 and AFG2. 
 
Data on children (Study III) 
Two-tailed Fisher’s exact test was used to explore associations between the presence of 
each toxin in Guinean compared to Egyptian children. The urinary levels of each 
aflatoxin species were also investigated. For samples below the detection limit for a 
given aflatoxin metabolite, a mid point value between the limit of detection and zero 
was assigned. Data were then log transformed to provide a normal distribution and the 
Students t-test (two-tailed, unpaired, equal variance was not assumed) was performed to 
compare the levels measured between the Guinean and Egyptian samples. Data were 
then back-transformed and are presented as geometric means with 95%CI. 
 
4.3.2. China Study (Studies IV and V) 
The data were analyzed using SPSS (Version 12.0) and SAS (Version 9.1.3). Urinary 
AFB1-N7-guanine during the 5 weeks intervention period was the primary variable. The 
study groups were compared during the intervention period at week 3 and at week 5. In 
addition, a comparison was made 5 weeks after the cessation of the intervention to 
determine if the urinary AFB1-N7-guanine had  returned to the baseline level. Urinary 
AFB1-N7-guanine was first dichotomised (negative vs. positive). Adjusted ORs, with the 
corresponding baseline urinary AFB1-N7-guanine included as a categorical covariate, 
were calculated from logistic regression models for each time point separately. Since 
each subject contributed to two binary outcomes during treatment, as a primary analysis 
models using GEE (Generalized Estimating Equation) methods were fitted, assuming an 
unstructured covariance matrix and a logit link. The analysis started from the model 
including treatment, baseline AFB1-N7-guanine, time and interaction between treatment 
and time as factors. The factors were retained in the model if they were significant at the 
0.10 level. The time effect and the interaction between treatment and time were non-
 79 
significant (p=0.280 and p=0.860, respectively), and were excluded from the final 
model. The final model was used to estimate the OR and the confidence interval. 
Due to the high rate of non-detectable values (values below the detection limit), the 
analysis of the mean levels of urinary AFB1-N7-guanine was conducted as a secondary 
analysis. The zero concentrations were transformed to the observed minimum value 
divided by two. The final distributions of AFB1-N7-guanine were skewed to the right, 
and therefore, all values were logarithmically (ln) transformed before the analysis. 
Analysis of covariance (ANCOVA) was applied with respect to the level of AFB1-N7-
guanine concentrations in urine, at weeks 3 and 5, and after the cessation of the 
intervention, separately. The corresponding ln-transformed baseline concentration was 
included as a continuous covariate. The baseline-adjusted group means and their 
differences were then back-transformed to the original units and the results are given as 
geometric means and ratios (probiotic/placebo) with 95% confidence intervals, 
respectively. To account for multiple comparisons in repeated measurements, the 
urinary concentration of AFB1-N7-guanine was analyzed using ANOVA for repeated 
measurements. Concentrations at weeks 3 and 5 were included as dependent variables 
and the baseline concentration was included as a continuous covariate. ANOVA for 
repeated measurements was applied to study 1) difference between study groups, 2) 
time-effect i.e. change during the intervention period and 3) interaction between 
treatment and time. 
Mann-Whitney U test was used to examine the differences of AFB-N7-guanine between 
the HBV-positive and the HBV-negative subjects. 
 
4.4. Ethical considerations  
The Egypt Study was approved by the Ethics Committee of the University of Kuopio 
and Kuopio University Hospital in Finland and by the National Research Centre Ethical 
Committee. The study was approved by the Comité National d’Ethique pour la 
Recherche en Santé in Guinea and by the ethics committee at the London School of 
Hygiene and Tropical Medicine, UK. 
The China Study was approved by the Ethics Committee of the University of Kuopio 
and Kuopio University Hospital in Finland and Ethical Committee of Sun Yat-Sen 
University in China. 
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All subjects were made aware of the content of the study and if they agreed to 
participate, a written informed consent was obtained. In Egypt, the mothers were 
approached by the nurses of the New El-Qalyub hospital, and in Guinea, researchers of 
the Institute Pasteur de Guinée conducted a series of public meetings to explain the 
project and to discuss the parental concerns. The mothers of all children participating in 
the study gave informed consent. In China, the students were approached by researchers 
of the Sun Yat Sen University. Each subject was informed that they could discontinue 
the study at any time. 
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5. RESULTS 
 
5.1. AFM1 in breast milk of selected Egyptian mothers and determining factors 
(Studies I and II) 
 
Presence of AFM1 and dietary, socioeconomic and demographic factors affecting the 
levels of AFM1 in breast milk (Study I) 
AFM1 was detected in the breast milk of 138 from the 388 screened Egyptian mothers 
(35.5%). The mean level of AFM1 was 27 pg/ml milk (range 5.6-5131). The presence of 
AFM1 in breast milk was influenced by the frequency of corn oil consumption, the 
working status of the mothers, the stage of lactation, the number of children and the 
body mass index (BMI) of the mothers (Table 11). 
AFM1 in breast milk was detected significantly more frequently (p=0.016) in mothers 
consuming corn oil on a daily basis compared to less frequent corn oil consumers. Out 
of the 262 mothers who were consuming corn oil on a daily basis, 104 (40%) tested 
positive for AFM1, while out of the 125 who were consuming corn oil on a weekly or 
monthly basis, only 34 (27%) were AFM1 positive. 
AFM1 was detected most frequently in breast milk during the first month of lactation. 
Fourteen of 24 mothers who were in their first lactation month were found to be AFM1 
positive (58%), while out of the 360 mothers at lactation stage > 1 month only 123 
(34%) were AFM1 positive. The frequency of detection of AFM1 in breast milk during 
the first month of lactation was significantly greater (p = 0.017) than that in subsequent 
months combined. 
Out of the 339 mothers who did not work, 129 (38%) were found to have detectable 
AFM1 in their breast milk, while out of the 43 mothers who were employed, only 7 
(16%) had detectable breast milk AFM1 levels (p = 0.005). AFM1 was detected more 
frequently in obese women (BMI >30) (25 AFM1 positive out of 51 obese women, 
49%) compared to those who were either overweight (BMI>25) (58 out of 171 
overweight women, 34%) and those whose BMI was <25 (34 out of 114 women, 30%) 
(p=0.031). 
 
 82 
Table 11. Factors significantly associated with the presence of AFM1 in breast milk of 
Egyptian mothers 
Multivariate model Univariate  
Without BMI Without corn oil 
Mothers (n) AFM1 
positive 
% (n) Unadjusted 
p-values 
Adjusted
p-values 
Adjusted OR 
(95%CI)  
Adjusted
p-values 
Adjusted OR 
(95%CI) 
Mother’s age - 0.460 0.051 0.95 (0.91-1.00) 0.014 0.94 (0.89-0.99) 
Working status 
   non-working (339) 
 
38 (129) 
 
0.005 
 
0.012 
 
3.01 (0.14-0.78) 
 
0.018 
 
2.87 (1.2-6.87) 
   working (43) 16 (7)    
Number of children# 
   2-7 (275) 
 
38 (105) 
 
0.104 
 
0.036 
 
1.81 (0.31-0.96) 
 
0.025 
 
1.99 (1.09-3.64) 
   1 (109) 29 (32)      
Lactation stage* 
   <1month (24) 
 
58 (14) 
 
0.017 
 
0.004 
 
3.94 (0.10-0.63) 
 
0.028 
 
3.57 (1.15-1.09) 
   ≥1 months (360) 34 (123)    
Corn oil consumption 
   daily (262) 
 
40 (104) 
 
0.016 
 
0.002 
 
2.21 (0.27-0.74) 
 
- 
 
- 
   weekly/monthly (125) 27 (34)    
BMI 
   ≤25 (not overweight) (114) 
 
30 (34) 
 
0.031 
- 
 
- 
 
0.011** 
 
 
 
   25-30 (overweight) (171) 34 (58)  - - 0.578 1.16 (0.68-1.99) 
   ≥30 (obese) (51) 49 (25)  - - 0.004 3.01 (1.43-6.33) 
#including the newborn child, *the number of months that mother has been breastfeeding, 
**overall effect of BMI to AFM1 presence 
 
 
In multivariable models however, BMI and corn oil consumption were collinear to each 
other which violated the assumptions of the model and excluded them from being 
present in the same model. Therefore, separate models including either of these two 
factors were generated. When BMI was taken into consideration, mother’s age, non-
working status, having more than one child, early lactation stage (<1 month), and 
obesity appeared to be strong predictors of the presence of AFM1. Non-working 
mothers were 2.87 times more likely to be AFM1 positive than the working mothers (p= 
0.018), having more than one child almost doubled the risk of being AFM1 positive (p= 
0.025), and early lactation stage (<1 month) seemed to be a strong predictor of the 
presence of AFM1 with an OR of 3.57 (p= 0.028). BMI had a significant overall effect 
to the AFM1 presence (p= 0.011). There was no difference in AFM1 frequency for 
overweight mothers (BMI 25-30) compared to those with BMI ≤25 (p= 0.57), though 
obese mothers (BMI ≥30) had a three times greater risk of being positive for AFM1 than 
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those with BMI ≤25 (p= 0.004). In the multivariate corn oil consumption model 
(replacing BMI), mothers with daily corn oil consumption had a 2.21 times greater risk 
of being AFM1 positive than the non-frequent consumers (p= 0.002). Replacing BMI 
with corn oil in the model did not alter significantly the strengths of the associations 
between the other variables and the presence of AFM1 (Table 11). 
Consumption of other grain products, milk and milk products, meat, fish, legumes, 
cotton seed oil, dried fruits and peanuts did not exhibit any significant associations with 
the presence of AFM1 in breast milk (p >0.05). 
 
Longitudinal assessment of AFM1 in breast milk of Egyptian mothers (Study II) 
Fifty mothers who were selected for the follow up had a mean AFM1 level of 137 pg/ml 
(range 10-5131) in their breast milk. A total of 443 samples were collected during the 
12 months follow up period, and AFM1 was detected in 248 (56%) of the samples 
(mean for all samples 24 pg/ml milk, range 5.6-5131). During the summer months 
(May- September, n=136 breast milk samples), 121 (89%) samples had detectable 
AFM1 levels (mean 31 pg/ml, range 4.3-609) (Table 12). The highest percentage of 
positive samples occurred in June (96%) and the lowest in February (16%). 
 The AFM1 levels followed the same pattern, showing higher levels during the summer 
months, highest mean AFM1 level in July (64 pg ml-1 milk, range 6.3-497) and the 
lowest mean level in January (8 pg ml-1 milk, range 4.2-108). However, the individual 
sample with the greatest AFM1 level (889 pg/ml milk) was obtained in April. 
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Table 12: The percentage of positive samples and the levels of AFM1 in breast milk of 
Egyptian mothers during the 12 months of follow up 
 
n total AFM1 levels (pg/ml milk) 
 
 
 
number of AFM1 positive 
samples (%) mean* range 
January 50 12 (24) 8 4.2–108 
February 49 8 (16) 12 4.8–275 
March 50 28 (56) 18 5.0–181 
April 50 20 (40) 36 5.7–889 
May 26 23 (88) 40 4.6–609 
June 26 25 (96) 28 4.5–228 
July 26 24 (92) 60 6.3–497 
August 29 22 (86) 15 4.5–127 
September 29 24 (83) 14 4.3–63 
October 29 22 (76) 13 5.3–110 
November 29 21 (72) 28 4.9–360 
December 50 16 (32) 12 9.2–61 
*The zero values have been replaced by the detection limit value divided by 2 (2.1 pg/ml milk) 
 
During the follow up period, the factors determining the temporal variation of AFM1 
were the months of breast milk sample collection (January to December) (p< 0.001), the 
duration of lactation in months (lactation) (p= 0.003), and the peanut consumption over 
the week prior to sample collection (peanuts) (p= 0.061) (Table 13). The month where 
the breast milk sample collection took place appeared to be the dominant factor 
determining AFM1 presence. Summer months (May-September) were the months with 
the highest risk of aflatoxin presence, with June presenting an OR of 63 [95% CI: (7.7, 
522)] (Figure 23). Winter months (December–February) had the lowest AFM1 presence 
risk [OR December 1.59, 95% CI: (0.65, 3.8), January (reference month) 1, February 
0.51, 95% CI: (0.18 1.4)]. The duration of lactation was fitted as a linear term into the 
model. Every month increase in the lactation stage contributed to a significant 8% 
increased risk of AFM1 presence [OR= 1.08, 95% CI: (1.02, 1.13)]. Peanut consumption 
was weakly related to AFM1 (p= 0.061) with mothers consuming peanuts during the 
week prior to sample collection having a 69% elevated risk of being AFM1 positive 
[OR= 1.69, 95% CI: (0.9, 2.9)]. 
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Table 13. Factors affecting the temporal variation in the level of AFM1* (multilevel 
modeling results). 
Covariate p OR CI lower CI upper 
Lactation 0.003 1.08 1.02 1.12 
Peanuts 0.061 1.69 0.98 2.91 
January**  1.00   
February 0.190 0.51 0.18 1.40 
March 0.005 3.42 1.43 8.18 
April 0.268 1.65 0.68 3.97 
May 0.000 22.38 5.63 88.93 
June 0.000 63.31 7.67 522.65 
July 0.000 27.55 5.57 136.37 
August 0.000 17.24 4.91 60.54 
September 0.000 11.60 3.54 37.97 
October 0.000 6.94 2.29 21.02 
November 0.001 5.80 1.97 17.11 
December 0.308 1.59 0.65 3.88 
*The outcome measure was taken to be the presence or absence of a detectable level of AFM1 in 
the breast milk samples, **January was used as the reference month.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*number of mothers 
 
Figure 23. Seasonal effect on the risk of AFM1 presence in breast milk of Egyptian 
mothers. 
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During the follow up period, aflatoxins B1 (AFB1), B2 (AFB2), G1 (AFG1) and G2 
(AFG2) were occasionally observed in the breast milk samples (Table 14) with AFG1 
being the compound most frequently detected (6.8%, 30/443). 
 
                    Table 14. Frequency of aflatoxin detection in breast milk 
Aflatoxins n total % of positive samples (n) 
AFM1 443 56 (248) 
AFB1 443 2 (9)  
AFB2 443 2.5 (11)  
AFG1 443 6.8 (30)  
AFG2 443 1.6 (7)  
 
Most of the positive samples were collected during the summer months (May-
September): out of the 9 samples that contained AFB1, 7 were detected during summer 
(78%), with the respective frequencies for AFB2, AFG1 and AFG2 being 54% (6/11), 
63% (19/30), and 43% (3/7). Winter months (December-February) had rather low 
frequencies of detection (AFB1 1/9, AFB2 2/11, AFG1 3/30, AFG2 2/7). These 
aflatoxins generally occurred in samples positive for AFM1. Out of the 9 samples that 
were AFB1 positive, 7 were also positive in AFM1 (78%), while out of the 11 AFB2 and 
7 AFG2 positive samples, 8 (73%) and 4 (57%) were AFM1 positive, respectively. These 
associations were not significant, whereas the presence of AFM1 was significantly 
correlated (p<0.001) with AFG1 presence; 27 out of the 30 AFG1 positive samples were 
also AFM1 positive (90%). There was no significant association between the presence 
of any other pair of toxins (e.g. AFG1 and AFG2). 
 
5.2. Urinary biomarkers of aflatoxin exposure in young children from Egypt and 
Guinea (Study III) 
 
The urinary levels of different aflatoxins were measured in samples collected from 
Egyptian children who were subjected to  a moderate aflatoxin exposure, and from 
Guinean children representing a high aflatoxin exposure. Aflatoxins were less frequently 
present in urine of the Egyptian than Guinean children (38% vs. 86%). The difference in 
prevalence was statistically significant for most of the detected toxins: AFB1 (2 vs. 16%, 
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p= 0.016), AFB2 (10 vs. 58%, p= 0.000), AFG1 (4 vs. 2%), AFG2 (24 vs. 36%, p= 0.275) 
and AFM1 (8 vs. 64%, p= 0.000) (Table 15). 
 
Table 15. Frequencies of detection of different aflatoxins in the urine samples collected 
from the Egyptian and Guinean children 
*two-tailed Fishers exact test, **The limit of detection was determined by spiking blank urines 
with aflatoxin standards. The value varies due to the different fluorescent properties of the 
aflatoxin metabolites. 
 
Also the levels of the aflatoxins excreted in the urine were higher in the Guinean 
children. The geometric mean level of AFM1 was 6-fold higher in the urine from the 
Guinean children, and the other aflatoxins, AFB1, AFB2, and AFG2, but not AFG1 were 
also observed at higher geometric mean levels (Table 16). 
 
Table 16. Levels of different aflatoxins (pg/ml) in the urine samples of the Egyptian 
and Guinean children. 
 Average (range)# 
Geometric mean (95% CI)##  
 Egypt (n=50) Guinea (n=50) P value* 
AFB1 
 
189 
13.2 (11.8, 14.6) 
2682 (179-18000) 
26.6 (16.3, 42.9) 0.007 
AFB2 
 
1.4 (0.8-2.2) 
0.2 (0.2, 0.3) 
5.7 (0.6-43) 
0.8 (0.5, 1.3) <0.001 
AFG1 
 
76 (72- 81) 
26.0 (24.5, 27.7) 
709  
26.6 (23.3, 30.6) 0.77 
AFG2 
 
2.2 (0.85-8) 
26.0 (24.5, 27.7) 
19 (1.4-199) 
26.6 (23.3, 30.6) 0.008 
#The arithmetic mean and range refer to those samples that are positive only. ##The geometric 
mean values are calculated including all samples. A mid-point value between the limit of 
detection and zero was assigned to those samples that were below the limit of detection. *P 
values are based on natural log transformed data, using two tailed unpaired student T-test. 
Equal variance was not assumed. 
 
 
 
 
 n of positive samples (%)  Limit of detection** 
 Egypt (n=50) Guinea (n=50) P value* pg/ml 
AFB1 1 (2) 8 (16) 0.016 25 
AFB2 5 (10) 29 (58) 0.000 0.35 
AFG1 2 (4) 1 (2) 1 50 
AFG2 12 (24) 18 (36) 0.275 0.8 
AFM1 4 (8) 32 (64) 0.000  5 
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5.3. Reduction of aflatoxin exposure by probiotic supplementation in young male 
students from China (Studies IV and V) 
 
300 young male students from Southern China were screened for the presence of AFM1 
in urine and of these, 90 with detectable AFM1 in urine were selected for an intervention 
aiming to determine whether administration of probiotic bacteria could reduce aflatoxin 
exposure by preventing its absorption from the small intestine. The urinary excretion of 
AFB1-N7-guanine was used as a biomarker for reduced absorption of AFB1. 
The median urinary AFM1 screening concentration of those participating in the 
intervention (n=83) was 0.08 ng/ml (IQR 0.06 to 0.12), and the median baseline value 
(prior to the intervention) of AFB1-N7-guanine 0.38 ng/ml (IQR 0.0 to 2.15) (study IV). 
The percentage of subjects with detectable (positive) AFB1-N7-guanine levels was not 
significantly different between the treatment arms at baseline: 51.3% (20 of 39 samples) 
of probiotic and 59.5% (25 of 42 samples) of placebo samples (study V). The 
percentage of samples with negative values tended to be higher in the probiotic arm than 
in the placebo arm during the intervention period of 5 weeks (OR=2.63, p=0.052) 
(Table 17) but the effect of probiotic was no longer seen 5 weeks after the cessation of 
the intervention (post-intervention), where the difference between groups was not 
significant (p=0.289). 
 
Table 17. Effect of the probiotic intervention on the proportion of urinary AFB1-N7-
guanine values below the detection limit* 
 Probiotic (n=39) Placebo (n=42) Probiotic vs Placebo**  
 % negative % negative OR (95% CI) P value 
Baseline 49 41   
Intervention-week 3 56 36 2.88 (0.89, 9.39)  
Intervention-week 5  62 43 2.43 (0.78, 7.61)  
Total***   2.63 (0.99, 6.95) 0.052 
Post-intervention period  39 45 0.58 (0.21, 1.59) 0.289 
*The probiotic group received Lactobacillus rhamnosus LC705 and Propionibacterium 
freudenreichii ssp shermanii (1:1 wt/wt) at a dose level of 2-5 x 1010 colony forming units/day 
**ORs were calculated with the use of logistic regression analysis, where baseline AFB1-N7-
guanine was included as a categorical covariate 
***Data was corrected by generalized equation equations before analysis. 
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Probiotic administration led to a decrease in the urinary level of AFB1-N7-guanine. The 
reduction was 36% at week 3 and 55% at week 5, but had disappeared during the 5-
week post intervention period (Figure 13). The geometric mean during the intervention 
period for the probiotic group was 0.24 and that for the placebo group 0.49 ng/ml, and 
the ratio probiotic:placebo was 0.49 (95% CI: 0.30, 0.80, p=0.005). After the cessation 
of the intervention, the difference between groups was no longer statistically significant 
(p=0.703). 
 
Figure 24. Urinary levels of AFB1-N7-guanine in healthy Chinese males during the 
probiotic intervention, and post intervention period. The values are geometric means of 
39 and 44 subjects in the probiotic and placebo groups, respectively. 
AFB1-N7- 
guanine  
(ng/ml) 
Baseline           week 3         week 5        post-intervention 
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6. DISCUSSION 
 
Our study demonstrated the presence of aflatoxins or their metabolites in milk samples 
of mothers from Egypt and urine samples of young children from Egypt and Guinea as 
well as in young Chinese adults. Children are a highly susceptible population to 
environmental toxicants (Landrigan 1999), and early life exposure to carcinogens may 
result in a greater lifetime risk of cancer (Miller et al. 2002). In addition, the result of 
exposure to xenobiotics may be different in children from those encountered in adults, 
both in the degree of severity of effect and in the nature of the effect (Miller et al. 
2002). An example of such an outcome for aflatoxins is postnatal growth retardation. 
Aflatoxins can cross the human placenta (Denning et al. 1990, Wild et al. 1991) and 
young infants may be exposed to aflatoxins from breast milk (Wild et al. 1987, El-
Nezami et al. 1995) or when they are weaned onto solid foods (Gong et al. 2003). 
 
6.1. AFM1 in breast milk and maternal aflatoxin exposure (Studies I and II) 
 
AFM1, which is carcinogenic and cytotoxic (IARC 1993) with potentially important 
implications in immunocompetence and growth, was detected in 138 out of the 388 
breast milk samples from individual mothers (35.5%) during May-September 2003. The 
median AFM1 level of the positive samples was 13.5 pg/ml of milk (range 5.6- 5131 
pg/ml). 
The frequency of AFM1 detection in these mothers was higher than that previously 
reported from this region (El-Shewey 1992), although this may partly reflect improved 
analytical sensitivity. El-Shewey et al. (1992), reported 11% positive samples (22 out of 
200) with mean levels 160 pg/ml (range 120-200 pg/ml). In that previous study, the 
determination of aflatoxins in human milk was performed by thin layer chromatography 
(TLC), a much less sensitive method than the HPLC technique used in our study. 
According to our study as well as the results of El-Shewey et al, the AFM1 level in the 
breast milk of the Egyptian mothers is lower than the levels reported elsewhere. For 
example, the median levels of positive samples and the detection rates of two of the 
most recently published studies on AFM1 in breast milk levels were 560 pg/ml and 92% 
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in the United Arab Emirates (Abdulrazzaq et al. 2003), and 664 pg/ml and 44% in 
Thailand (El-Nezami et al. 1995). 
Fifty mothers identified as being AFM1 positive in the screening phase of the study 
were recruited for a year of follow up with monthly collections of breast milk samples. 
AFM1 was detected in 56% of the collected breast milk samples with the median levels 
of all samples being 5.76 pg/ml (range 4.2-889). The highest detection rates of AFM1 in 
the breast milk occurred during the summer months (May-September) (89%, 121/136), 
with the highest rate found in June (96%). The median AFM1 concentration of the 
positive samples during May-September was 11.44 pg/ml milk (range 4.3-609), while 
that in June was 12.06 pg/ml. However, since the mothers were selected on the basis of 
AFM1 breast milk levels, they do not represent the general aflatoxin exposure of the 
population in this region but that of an exposed group. 
 
Calculations of maternal AFB1 and child AFM1 daily exposures 
AFM1 in the breast milk is a biomarker of children’s exposure to this carcinogen but can 
also be considered as a biomarker of maternal exposure to AFB1. However, there are 
certain limitations in estimating the average daily aflatoxin intake of the mother and the 
infant based on breast milk aflatoxin levels due to factors influencing the amount of the 
aflatoxin that passes into the milk. These factors include the variation of the maternal 
dietary exposures, the total milk volume, the fat and protein content of the milk, the 
contribution, if any, of aflatoxin or its metabolites potentially stored in fat reserves, the 
intra-individual differences in conversion of AFB1 to AFM1 (e.g. CYP 1A2 
polymorphisms), and the amount of milk consumed by the infant. Despite these 
difficulties, estimates can be made based on the assumptions that the average daily milk 
volume is 500 ml and AFM1 in human milk represents 0.09%–0.43% of dietary intake 
of AFB1 (Zarba et al. 1992). Using the median AFM1 levels during the screening period 
(Study I) (13.5 pg/ml milk), the average intake of AFM1 by the infants can be calculated 
as being 6.75 ng AFM1/day, while the intake by mothers is estimated to be 1.5-7.5 µg 
AFB1/day (Table 18). For the follow up period (Study II), using the median AFM1 
levels during June (12.06 pg/ml) to reflect consumption of contaminated food at peak 
exposure, the estimated AFM1 intake by the infants was 6.03 ng/day infant whareas that 
of AFB1 by the mothers was in the range of 1.4-6.7 µg/day. These levels from the two 
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studies are very similar to each other, reflecting the high exposures during the summer 
months. However, the median level of all samples collected over the year (5.76 pg/ml) 
represents perhaps a more realistic value, giving estimated intakes of 2.88 ng AFM1/day 
and 0.7-3.2 µg AFB1/day for the average infant and mother, respectively. It must be 
emphasized that , since the mothers were pre-selected on the basis of AFM1 breast milk 
levels, they do not represent the general aflatoxin exposure of the population in the 
region but that of an exposed group, and thus the average exposure in this region will be 
lower than the above estimates. 
 
Table 18: Estimations of the maternal and infant daily aflatoxin intakes 
Maternal intake of AFB1** 
range 
AFM1 levels in breast milk 
median (pg/ml milk ) 
Infant intake of AFM1* 
average (ng/day) 
µg AFB1/day) (ng AFB1/kg bw/day) 
(Study I, May- September)     13.5 6.75 1.5-7.5 23-115 
(Study II, June)                        12.6 6.03 1.4-6.7 21-103 
(Study II, January-December) 5.76 2.88 0.7-3.2 10-49 
* Based on the assumption that average daily milk volume is 500 ml 
**Based on the calculation that AFM1 in human milk represents 0.09%–0.43% of dietary AFB1 
intake 
 
To obtain some perspective of the intakes of the Egyptian mothers, they can be 
compared with the average daily intake as calculated by the average contamination in 
the diet multiplied by the amount of food consumed by women in two high risk regions 
for aflatoxin exposure i.e. 8 µg AFB1 in Zhuqing, China (Wang et al. 2001), and 15.7 
µg total aflatoxins in The Gambia, West Africa (Groopman et al. 1992a). In comparison 
to these values, the dietary aflatoxin exposure level of the Egyptian mothers can be 
viewed as modest. 
Data assembled by Hall and Wild (Hall and Wild 1994) indicate that the range of 
estimated aflatoxin exposure based on the analysis of aflatoxins in foods was 3.5-14.8 
ng/kg bw/day in Kenya, 38.6-183.7 in Mozambique, 16.5 in South Africa, 4-115 in The 
Gambia, 11.7-2027 in southern Guangxi province of China, and 6.5-53 ng/kg bw /day in 
Thailand. These exposure rates however, are average estimations based on annual grain 
consumption, which is appropriate for cancer risk estimates because of the cumulative 
nature of this response. Doses in the short term may vary significantly from the average 
 93 
either because of seasonal variability or with variability associated with testing grain 
products for aflatoxins. The levels of maternal AFB1 exposure based on median levels 
of all milk samples in our study (10-49 ng/kg bw/day) are however at comparable 
levels. 
 
Estimations of potential health risk for the mothers and the breast feeding infants 
The results of epidemiological studies have indicated that  the dose considered as 
“virtually safe” or representing a risk level of 1 in 105 (giving a single HCC lifetime risk 
per 100 000 persons from the consumption of AFB1 contaminated foodstuffs) is 0.19 
ng/kg bw/day (Kuiper-Goodman. 1991). Lactating mothers fall into a special category 
of the population, and in the present study, the mothers were from a selected area 
known to have significant aflatoxin exposure. Consequently, the exposure estimates 
cannot be generalized to the general population. However, the potential health risk 
based on the above carcinogenic potency estimate cannot be assessed as negligible since 
the above reported safe level is clearly less than the estimated AFB1 exposure levels of 
the mothers in our study. 
Nevertheless, due to the limited passage of aflatoxins into the milk [0.09%–0.43% of 
dietary AFB1 intake is excreted as AFM1 into the milk (Zarba et al. 1992)] the levels of 
AFM1 detected in this study fall within the EU maximum permissible levels of AFM1 in 
infant ready-to-use milk formula (25 pg AFM1/ml). The Commission has stated that it is 
appropriate for the health protection of the infants and young children, a vulnerable 
population group, to establish the lowest maximum level, that is achievable through a 
strict selection of the raw materials used for the manufacturing of the infant milk 
formulae and baby foods (EC 2004 ). However, for genotoxic carcinogenic substances, 
such as aflatoxins, there is no threshold value below which the risk value for human 
health is equal to zero. 
 
6.2. Determinants of AFM1 in breast milk (Studies I and II) 
 
The presence of AFM1 in the breast milk of the 388 mothers was affected by the 
working status of the mothers, the number of children, the frequency of corn oil 
consumption, the body mass index (BMI) of the mothers, and their stage of lactation. 
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Furthermore, factors affecting the temporal variation of AFM1 were the month of breast 
milk sample collection, and the stage of lactation. The mothers that took part in the 
follow up were initially selected to be AFM1 positive and subsequently several other 
factors were found in these women i.e. non working, more than one child already (>1), 
and a high BMI were also found in the vast majority of these women. 
 
Working status and seasonal effect 
The non-working mothers were not employed, but mostly belonged in small rural or 
share-cropping communities; they were doing farm work and domestic chores. In share-
cropping communities, after the crops are harvested, they are left to dry over plastic or 
synthetic sheets, practices that may promote Aspergillus growth and toxin production 
(Turner et al. 2005a). Most of these crops are consumed locally by either the household 
or by others in the immediate community. In our study, a very strong seasonal effect 
was evident i.e. the high exposure period of summer corresponds to the hottest season. 
Aspergillus fungi are ubiquitous and they can grow on many foodstuffss whenever 
conditions allow. Food contamination frequently occurs during post harvest storage 
(Sylla et al. 1999, Turner et al. 2000, Wild et al. 2000) and presumably, the high risk of 
AFM1 presence during summer may reflect more severe aflatoxin exposure due to the 
accumulation of aflatoxin during storage under conditions promoting growth of 
Aspergillus. 
 
Food consumption 
A high BMI seemed to act as an indicator of the amount and type of food consumed 
including corn oil, with obese mothers consuming corn oil more frequently than the 
non-obese mothers (Study I). Worldwide, two of the major sources of aflatoxin 
exposure are groundnuts and corn, thus corn oil must be considered as a potential source 
of aflatoxin exposure in this region (El-Sayed et al. 2003, El-Shanawany et al. 2005). 
The fact that obese mothers had higher AFM1 levels than the non-obese possibly 
reflects the frequency of consumption of corn oil. This complicates understanding the 
contribution of corn oil to breast milk AFM1 level in our analysis when both factors 
were included in the analysis. Another theoretical explanation could be that aflatoxins 
also would be stored in body fat reserves, contributing in this way to higher aflatoxin 
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levels in breast milk. However, the presence of aflatoxins in animal fat tissue has not 
been reported (Hayes et al. 1977). 
During the follow up (Study II), the consumption of specific foods possibly 
contaminated with aflatoxin (corn and corn oil, cottonseed oil, peanuts) did not 
significantly relate to AFM1 presence. This may be due to a relatively steady pattern of 
food consumption throughout the year with the presence of AFM1 in breast milk 
reflecting the level of food contamination and not the frequency of food consumption. 
In addition, it could be the amount of consumption of specific foods rather than the 
frequency which may vary throughout the year, though we did not collect this additional 
dietary information in our questionnaire. 
 
Duration of lactation and number of children 
In the cross-sectional part of the study (Study I), the mothers at an early lactation stage 
(<1 month) were more frequently found to be positive of AFM1 than the other mothers. 
These mothers had given birth no more than 15 days before providing the breast milk 
sample. The relative proportions of milk components is known to vary significantly 
with the stage of lactation, especially at the beginning of lactation where proteins, fat-
soluble vitamins, phospholipids and cholesterol are present in much higher 
concentrations than they are in the mature milk (Lawrence 1999). It is possible that the 
changes in fat and protein content are important in terms of accumulation and 
mobilization of aflatoxins. However, during the follow up period (Study II), the risk of 
AFM1 presence was increased when the duration of lactation was longer (range of 
lactation months 3-29). This observation may reflect time-dependent changes in 
maternal physiology that alter the amount of toxin passing to the infant (Clewell and 
Gearhart 2002). These include adipose tissue levels, age, milk composition and volume, 
gradual weaning, and breast-feeding patterns. The presence of other children in the 
family (number of children >1) was also associated with a higher risk of AFM1 presence 
in milk. Previous childbirths, the number and length of previous lactations, and the 
period between childbirths, has been reported to affect significantly the concentrations 
of the highly lipophilic organochlorines stored in human fat (Harris et al. 2001). 
Unfortunately, for aflatoxins this kind of information is lacking in the literature. The 
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possibility that a high number of children is likely to be an indicator of lower socio-
economic status and therefore of a less varied diet cannot be excluded. 
 
6.3. Children’s aflatoxin exposure (Studies I and III) 
 
In developing countries, growth faltering is often associated with the quantity and/ or 
poor quality of foods, in addition to multiple other hazards (WHO 1995). In common 
with many developing countries (Shrimpton et al. 2001), Egyptian infants had a high 
frequency of stunting (height to age z-score ≤ -2, length faltering) (35.7%) and a 
moderate frequency of being underweight (weight to age z-score ≤ -2, weight faltering) 
(14.4%), based on WHO (1995) criteria. Older infants had lower HAZ and WAZ scores 
than the young children (Figure 25). Length faltering started immediately after birth, 
while weight faltering started at 3 months of age, after having been parallel to the 
reference for the first three months. This observed strong positive association between 
impaired growth and age is to be expected in developing country setting (Shrimpton et 
al. 2001). 
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Figure 25. Egyptian children’s growth. Mean weight for height Z-score (WHZ) (n= 
351), weight for age Z-score (WAZ) (n= 375), and height for age Z-score (HAZ) (n= 
322) by age (Study I). 
 
It has been claimed that high levels of aflatoxin-albumin adducts may be  associated 
with growth faltering in Beninese children, with a marked increase in aflatoxin exposure 
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occurring when children were weaned onto solid foods (Gong et al. 2003, 2004). 
Unfortunately, in the cross-sectional study (Study I), we did not have access to 
biomarkers of infant aflatoxin exposure in order to evaluate the contribution of 
aflatoxins to the growth impairment in the Egyptian fully breast fed (n=182) or partially 
breast fed (n=202) children. The modest maternal breast milk levels of AFM1 would 
indicate that overall exposures from milk or weaning foods appear to be relatively low. 
The levels of aflatoxin exposure of 50 of the above children was assessed and compared 
to the exposure of 50 Guinean children by measurement of aflatoxin metabolites in 
urine. Aflatoxins were less frequently present in Egyptian than in Guinean children 
(38% vs. 86%) with statistically significant differences in the prevalence for most of the 
detected aflatoxins: AFB1 (2% vs. 16%, p= 0.016), AFB2 (10% vs. 58%, p= 0.000), 
AFG1 (4% vs. 2%), AFG2 (24% vs. 36%, p= 0.190) and AFM1 (8% vs. 64%, p= 0.000). 
For AFM1 the mean level in Guinean samples was 18-fold higher than the 
corresponding value in Egyptian samples. 
The Guinean children were all HBV positive while the Egyptian children were all HBV 
negative as determined from HBsAg in serum. It has been previously reported that HBV 
infection significantly influences the AF-albumin adduct levels; HBV positive Gambian 
children having a higher level of AF-albumin than HBV negative children (Turner et al. 
2000). These authors proposed that liver injury could be an important modifier of 
aflatoxin metabolism and thus young children may be more severely affected than 
adults by HBV infection. However, in our study, the highly significant difference in the 
frequency and levels of exposures between these two regions is probably unlikely to be 
explained simply by a difference in HBV status of these children since though HBV 
status might possibly have a modest effect on the AFM1 metabolite, it is most unlikely 
to alter the levels of excretion of the parent compounds AFB1, AFB2, AFG1, AFG2 in 
urine. 
From the 50 Egyptian children, 30 children were fully weaned, and 20 were partially 
receiving breast feeding. 30% (6/20) of the partially breast-fed children were positive 
for aflatoxins (AFB1, AFB2, AFG1, AFG2), with all children being negative with respect 
of AFM1 in urine. In all, 43% (13/30) of the fully weaned were positive to aflatoxins. 
All Guinean children were fully weaned. Weaning status has been previously reported 
to contribute significantly towards higher aflatoxin exposures (Gong et al. 2003, 2004) 
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and partial breast-feeding may to some extent have protected the Egyptian children 
against higher exposures, due to the limited passage of aflatoxins into breast milk. 
A good correlation has been reported between AFB1 intake and urinary excretion of 
AFM1 (Zhu et al. 1987, Groopman et al. 1992a) and AFM1 has been used as an index 
for human exposure of AFB1 in molecular epidemiology studies. Based on average 
AFM1 levels [arithmetic means; Egypt 5.2 pg/ml urine (range 4-6.2) and Guinea 97 pg/ 
ml urine, (range 8-801)], the AFB1 daily exposure was estimated to be 0.2 and 3.8 µg for 
Egypt and Guinea, respectively. This calculation was based on the assumption that 1.5% of 
AFB1 intake is excreted in the urine in the form of AFM1 (Zhu et al. 1987) and that the 
average daily urinary volume of a 1.5-2 year old child is approximately 600 ml (Goellner 
et al., 1981) In the literature, there is a scarcity of urinary biomarker data and levels of 
aflatoxin exposure in children. Therefore comparisons can only be made with levels of 
adult aflatoxin exposure (Table 19). 
 
Table 19. Comparison of the calculated AFB1 children exposure with the reported 
AFB1 exposure in adults. 
Country Aflatoxin daily exposure Reference 
Egypt 
Guinea 
0.2*µg AFB1 Egypt, children 
3.8* µg AFB1 Guinea, children 
Study I 
Study III 
Gambia 8.2 µg, adult men (total aflatoxins) 
15.7 µg, adult women (total aflatoxins) 
(Groopman et al. 1992a) 
China 48.4 µg AFB1, adult men 
77.4 µg AFB1, adult women 
(Groopman et al. 1992c) 
China 14 µg AFB1, adult men 
8 µg AFB1, adult women 
(Wang et al. 2001) 
*calculations are based on average urinary AFM1 levels (arithmetic mean), on the assumption 
that 1.5% of AFB1 is excreted as AFM1 in urine (Zhu et al. 1987) and that the total daily urinary 
volume for children aged 1.5-2 years is 600 ml (Goellner et al. 1981). 
 
The presence of AFB1 and AFG1 was lower for both Guinea (16 and 2%, respectively) 
and Egypt (2 and 4%) in comparison to AFB2 and AFG2 (58 and 36% in Guinea and 10 
and 24% in Egypt). The lower frequencies of both AFB1 and AFG1 in the urine mostly 
likely reflect the higher conversion of these dietary aflatoxins to other metabolites in the 
liver. However, the arithmetic mean urinary levels of AFB1 and AFG1 (2682 and 709 
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pg/ml in Guinea, 189 and 76 pg/ml in Egypt) were higher than those of AFB2 and AFG2 
(5.7 and 19 pg/ml in Guinea, 1.4 and 2.2 pg/ml in Egypt). This may reflect the fact that 
in aflatoxin contaminated samples, AFB1 is the most frequent type of toxin being 
present in high amounts, followed by AFG1. AFB2 and AFG2 are typically present in 
much lower quantities (IARC 1993). The A. paraciticus species producing AFB1, AFB2, 
AFG1 and AFG2 are known to be widely distributed in Africa (IARC 1993). 
Nevertheless, the difference in urinary frequency will also be significantly influenced by 
the greater sensitivity of detection of AFB2 and AFG2 compared to AFB1 and AFG1 (see 
materials and methods for the limit of detection of each aflatoxin metabolite). 
 
6.4. Probiotic intervention (Studies IV and V) 
 
The primary goal of the intervention study was to determine whether administration of a 
commercially available mixture of probiotic bacteria could prevent/reduce the 
absorption of AFB1 from the small intestine (Study V). The results of the intervention 
were assessed on the basis of AFB1-N7-guanine in urine that was used as a marker of the 
biologically effective dose of AFB1. The median baseline AFB1-N7-guanine values were 
0.38 ng/ml (IQR 0.0 to 2.15) (Study IV); these levels are similar to those reported from 
other studies (Table 20). 
 
Table 20. The AFB1-N7-guanine excreted in the urine of young Chinese males in 
comparison to other reported urinary levels in adults. 
Country AFB1-N7-guanine 
Range (ng/ml) 
Reference 
China 0.0-2.15 Study IV 
China 0.3-1.81 (Qian et al. 1994) 
China 0.04-1.27* (Wang et al. 2001) 
Gambia 0.03-5* (Groopman et al. 1992a) 
*values were given as ng/day and expression as ng/ml are based on the assumption that the 
average adult daily urinary volume is 1600 ml (JEFCA 1998). 
 
Studies on the correspondence between individual dietary AFB1 exposure and the 
excretion of AFB1-N7-guanine in the urine have shown a dose-dependent relationship 
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between these two parameters (Groopman et al. 1992a, 1992b, 1992c) with about 0.2% 
of the oral AFB1 dose being excreted as AFB1-N7-guanine in urine (Groopman et al. 
1992c). Based on this estimation and on the assumption that average adult daily volume 
is 1600 ml (JEFCA 1998), the average dietary AFB1 intake of the Chinese students is 
calculated to be 304 µg/day or 5µg/kg bw/day. This value represents the exposure level 
of a group of selected Chinese subjects with verified aflatoxin exposure as indicated by 
the presence of AFM1 in their urine, and therefore is higher than other reported values 
for the Chinese population (Table 20). 
The levels of AFB1-N7-guanine adducts in the urine reflect the formation of AF-DNA 
promutagenic liver lesions involved in the cancer initiation process (Smela et al. 2001). 
Elevated urinary excretion of this aflatoxin-DNA adduct has been associated with an 
increased risk of HCC (Qian et al. 1994) and the importance of AFB1-N7-guanine 
relative to other urinary aflatoxin biomarkers as a predictor of HCC risk has been 
clearly shown from Qian et al (1994). The presence of the AFB1-N7-guanine adduct 
together with other AFB1 metabolites (AFM1, AFQ1, AFP1) significantly elevated the 
risk of HCC compared to the presence of the other metabolites alone. 
Diminished concentrations of AFB1-N7-guanine have been associated with a reduced 
risk in HCC in chemoprevention studies in animals (Roebuck et al. 1991). Loeb (2001) 
stated that a 2-fold reduction in mutation rates (as could be anticipated from the decline 
in DNA adduct burden achieved in the current study) could prolong the time between 
initiation and clinical manifestations of cancer from 20 or more years to 40 or more 
years. Given that the median age of diagnosis for HCC in many developing countries is 
less than 50 years (Hall and Wild 2003), such a delay could have a major impact in high 
risk areas. 
The results of this intervention clearly revealed probiotic supplementation as a feasible 
means to reduce the biologically effective dose of aflatoxin in individuals with 
detectable aflatoxin exposure, providing a potentially effective approach in the 
reduction of the risk of HCC development in high risk regions. In addition, probiotic 
bacteria have by definition a beneficial impact on the health of the host that may be 
advantageous especially in a developing country setting where the population is 
exposed to multiple infectious and nutritional hazards. 
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7. SUMMARY AND CONCLUSIONS 
 
In the present work, we 1) investigated the patterns and levels of maternal and child 
aflatoxin exposure in a selected group of mothers and children in Egypt, 2) compared 
the exposure levels of Egyptian children with children from Guinea, a country with a 
recognized high aflatoxin exposure, and 3) assessed the effectiveness of probiotic 
supplementation in reduction of the biologically effective dose of aflatoxin exposure in 
a highly exposed region of southeastern China. From this work, the following 
conclusions can be drawn: 
 
• Aflatoxin contamination of breast milk in the Egyptian mothers was frequent 
although at moderate levels. Several socioeconomic, demographic, dietary or 
environmental factors affected the presence and levels of AFM1 in breast milk, 
with the most dominant being a seasonal effect. This kind of seasonality of 
aflatoxin exposure has been repeatedly reported in the literature. 
 
• In the comparison of the Egyptian and Guinean children, the aflatoxin exposure 
of the Guinean children was more prevalent and occured at higher levels. 
 
• The results of the intervention in young Chinese adults clearly showed that 
probiotic supplementation could impair the bioavailability of dietary aflatoxins 
and reduce their biologically effective dose. 
 
Overall, these results highlight that measures to reduce aflatoxin exposure in infants, 
young children, and young adults in developing countries are important, while probiotic 
supplementation could provide an affordable and feasible means to reduce the aflatoxin 
exposure and possibly the incidence of liver cancer in aflatoxin endemic areas. 
Breast milk is without doubt the best type of infant nutrition, providing multiple 
advantages for the developing child. Additionally, extended breast feeding may play a 
protective role against higher aflatoxin exposure through the delayed introduction of 
weaning foods which may have a higher aflatoxin content. In Egypt, weaning foods are 
the foods consumed by the rest of the household, and the fact that the mothers were 
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exposed means also that children would also be exposed when they start to consume the 
same diet as the other family members. However, AFM1 is carcinogenic and cytotoxic 
with potentially important implications on immunocompetence and growth and possibly 
also on disease risk later in life. It is therefore advantageous if the AFM1 levels in breast 
milk could be kept as low as possible. For genotoxic carcinogenic substances such as 
aflatoxins, there is no threshold value below which the risk value for human health is 
equal to zero. Moreover, babies, infants and young children are critical groups when 
considering exposure to contaminants such as aflatoxins, since they consume large 
quantities of food in comparison to their body weight. 
The identification and understanding of factors determining the presence of toxicants in 
human milk is important for the implementation of intervention strategies aimed at 
reducing aflatoxin exposure. An intervention utilizing probiotic bacteria to reduce 
maternal exposure would be predicted to have a beneficial impact on the fetus and on 
the infant’s exposure to AFM1 in breast milk. This may be best achieved by 
incorporating into the diet traditional foods fermented with selected aflatoxin binding 
starter bacteria. The results of this present work have been utilized in the planning and 
design of a probiotic intervention in mothers and young infants currently ongoing in 
Egypt. 
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